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CHAPTER 1 
INTRODUCTION 
2 
INTRODUCTION 
In patients with severe liver disease, hepatic dysfunction may deteriorate 
to such an extent that conservative medical treatments are no longer 
sufficient to maintain the, for life essential, liver functions. For these 
patients the transplantation of a donor liver represents the only hope for 
survival. 
Livers can be transplanted m two different manners: either in the 
orthotopic position after removal of the diseased native liver, or m a 
heterotopic position as an auxiliary liver. 
1.1 Orthotopic liver transplantation 
Since the first orthotopic liver transplantation (OLT) m man was per-
formed by Starzl in 19631, more than 2000 orthotopic liver transplantations 
have been performed all over the world2•3. During the sixties and seventies 
the results were rather poor with one year survival rates of about 30%3•4. 
Uncontrollable bleeding leading to large amounts of blood loss was the main 
cause of death in these years3•4. After 1980 important improvements in 
surgical techniques, anesthesiologic management and changes in immuno-
suppressive treatment have contributed to a steady increase of the survival 
rate. This has encouraged more centers in the world to start a liver 
transplantation program for liver patients for which no satisfactory medical 
therapy is available, and the number of transplants the world over is now 
almost doubling annually5. Although most centers now report one year 
survival rates of 60-70%, OLT is still associated with a high intraoperative 
blood loss and the need for large blood transfusions3,6 Even in a large 
center as Pittsburgh, with a long experience, the mean intraoperative use of 
red blood cell concentrates and fresh frozen plasma in adult first-time liver 
transplants in 1987 was still 23 and 12 U, respectively and transfusions of 
more than 50 U red blood cell concentrates are no exception (Dr. J.H. Lewis, 
personal communication). Intraoperative use of red blood cell concentrates of 
more than 30 U has been found to be associated with almost 70% mortality 7. 
During the last 25 years many investigators have tried to elucidate the 
origin of this hemorrhagic diathesis. This has 
papers on the changes in hemostasis during 
predispose for, or correlate with a high 
resulted in a large number of 
OL T and on factors that may 
intraoperative blood loss. In 
general, 
due to 
it has been observed that a poor preoperative hemostatic function 
the underlying liver disease and the occurrence of specific intra-
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operative deteriorations in the hemostatic system are factors that play an 
important role in the development of bleeding complications in many 
patients. However, several investigators have proposed different and some-
times contradictory explanations for their observations and the exact 
mechanisms underlying the intraoperative hemostatic deterioration are still 
not fully understood. 
1.2 Auxiliary liver transplantation 
The first auxiliary liver transplantation was performed by Absolon et aL 
in 1964 8. The initial results of auxiliary liver transplantation were discour-
aging and the number of auxiliary liver transplantations performed so far is 
much lower than that of OLT. Until 1985, this type of liver transplantation 
was reported in a total of 48 patients and only two patients survived longer 
than one year9. In spite of these disappointing results the concept of 
auxiliary liver transplantation was never abandoned completely. Some groups 
have tried to clarify the reasons of failure and have further investigated 
new surgical techniques in experimental models. Much of this research work 
has been performed in The Netherlands and it has led to the development of 
an improved method using a partial liver graftlO,ll_ After the technical 
feasibility of this modified technique of auxiliary partial liver transplantation 
(APLT) was proven in a large number of experimental studies10-l 4, it was 
decided to perform this technique in humans also. APLT is currently used in 
the University Hospital of Rotterdam to treat patients with end-stage liver 
disease, which were rejected for OLT, or in patients with acute hepatic 
failure15•16 
APLT may theoretically be associated with a reduced risk of bleeding 
since the surgical trauma is less severe. Furthermore, there is no anhepatic 
phase during the operation, which may prevent the occurrence of serious 
intraoperative changes in the hemostatic system. This may be an important 
advantage in patients with a poor preoperative condition and at too high a 
risk for successful OLT. However, knowledge about the effect of this type of 
liver transplantation on hemostasis is limited. 
1.3 Objectives of the study 
In this thesis studies on hemostatic changes during and after OLT and 
APL T are described. The studies were designed to investigate the mecha-
nisms underlying specific hemostatic disorders that occur during both types 
of liver transplantation and to study the differences between APLT and OLT, 
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concerning the effects on the hemostasis mechanism. 
The second chapter gives an extensive overview of the literature on 
hemostasis in liver transplantation. The different hemostatic changes and 
the proposed underlying mechanisms which have been described in liver 
transplantation are evaluated and discussed. Based on this review the 
working hypothesis for the studies described in the next chapters were 
formulated. 
The aims of these studies were: 
1. To compare orthotopic and auxiliary partial 
the changes m the hemostatic system and 
animal studies (chapter 3). 
liver transplantation regarding 
intraoperative blood loss in 
2. To study the role of the donor liver in the origin of hemostatic deterio-
rations in animal studies, after connection of the graft to the recipient's 
blood circulation (chapter 4). 
3. To develop a practical laboratory system for 
toring of hemostasis and anticoagulant therapy 
procedures (chapter 5). 
the intraoperative 
during major 
moni-
surgical 
4. To study the origin and systemic effects of hyperfibrinolysis in orthotopic 
liver transplantation (chapter 6). 
4. To make a first evaluation of the changes in hemostasis that may occur 
during and after auxiliary partial liver transplantation in humans (chapter 
7). 
5. To study the fibrinolytic system during auxiliary partial liver transplan-
tation in humans and the mechanisms that cause hyperfibrinolysis (chapter 
8). 
6. To develop an in vitro model for investigations on the regulation of 
hemostasis proteins synthesis by culturing primary human hepatocytes 
(chapter 9). 
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2.1. INTRODUCTION 
More than twenty five years ago, Starz1 reported the first clinical 
application of orthotopic liver transplantation (OLT) (!). The patient, who 
died of blood loss due to hemostatic disturbances, had complications that 
would become a serious problem In subsequent patients. Although the 
success rate of OLT has improved markedly in recent years, and OLT is now 
an accepted treatment for patients with end-stage chronic liver disease 
(2,3), massive blood loss is still a major problem (4,5,6). In the recently 
published first Report of the European Liver Transplant Registry, bleeding 
complicat:ons were the most frequent (34%) cause of death intraoperatively 
and during the first postoperative week (7). Several investigators have 
demonstrated that large peri-operative blood loss is correlated with a high 
mortality (9, 10). Patients undergoing OLT who received less than 30 u of red 
blood cells had a survival rate of 70%, whereas the survival rate decreased 
to about 14% in patients receiving 30 U or more (8). Disturbances in 
hemostasis appeared to be a major contributing factor to a high blood loss 
(9,11) and surviving and non-surviving cases of OLT can be partly classified 
by discriminant analysis of hemostasis parameters (12). 
Many studies have examined the pathogenesis of the hemorrhagic dia-
thesis m OLT and have contributed to a better understanding of the 
hemostatic changes that occur in OLT. Results of several studies however 
are contradictory. The use of different operation techniques and manage-
ment procedures and variations in assay methods makes comparison of the 
results difficult. The relation between specific hemostatic disorders and 
bleeding complications is still a matter of debate. 
To have a better overview of the intraoperative changes in hemostasis 
that have been found in clinical and experimental OLT and the underlying 
processes we have surveyed the literature. In view of the renewed interest 
in the heterotopic transplantation of an auxiliary liver graft, the effects of 
auxiliary liver transplantation on hemostasis will be compared with those 
induced by OLT. 
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2.2. THE HEMOSTASIS SYSTEM AND THE LIVER 
Extensive research on hemostasis has led to a marked development of 
this field of medicine during the last decade. New proteins have been 
identified and more accurate assays have become available. A schematic 
presentation of the hemostatic system, based on present insights is given in 
figure 1. 
The hemostatic mechanism is currently regarded as a dynamic balance 
between coagulation and fibrinolysis. Coagulation results in the formation of 
a fibrin clot and fibrinolysis leads to the resolution of fibrin clots. Under 
physiological conditions activities of both processes are in balance and 
neither thrombotic events nor bleeding disorders are seen. Either enhanced 
formation or delayed resolution 
a delayed formation and an 
fibrin deposition. This means 
may lead to increased fibrin deposition. Both 
accelerated removal may result in decreased 
that thrombosis or bleeding may be due to 
defects in the coagulation 
reviews see 13,14). 
system or in the fibrinolytic system or both (for 
The liver plays 
fibrinolytic proteins 
the liver contributes 
an important role in 
(15,16). In addition, 
to the clearance 
the 
the 
of 
synthesis of coagulation and 
reticulo-endothelial 
hemostasis factors 
system of 
and their 
degradation products (17, 18). In chronic liver disease, disturbances of these 
functions may lead to complex hemostatic disorders (15,19). The hemostasis 
disorders are often complicated by thrombocytopenia and 
tion and by a defective platelet-vessel wall interaction 
by platelet dysfunc-
(15,20). Bleeding 
complications in patients with severe liver disease are often found in 
combination with reduced levels of clotting factors (21,22), increased 
fibrinolytic activity (21,23) and changes in blood platelets (20,24). 
Changes in coagulation and 
different types of liver surgery. 
liver surgery, R6 (25) pointed 
fibrinolysis are also encountered during 
In an review of hemostatic problems in 
out that dangerous defects seldom occur 
during most surgical procedures of the liver, but that they may become a 
threat during liver transplantation. 
The preexisting hemostatic disorders in cirrhotic patients undergoing 
OLT, in combination with the specific 
contribute largely to the complexity of 
patients. 
intraoperative hemostatic changes, 
hemostatic management of these 
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Fig. 1. Schematic presentation of the hemostatic system. 
- activation 
____, 1 inhibHion 
~--> destruction 
After contact activation or tissue activation each activated (a) coagu-
lation factor converts the next coagulation factor into its enzymatic active 
form. Blood clots when thrombin (IIa) converts fibrinogen into fibrin. Fibrin 
formation is regulated by several activating and inhibiting pathways. The 
most important inhibitors of the coagulation system are antithrombin III 
(A T-Ill) and protein C, with its cofactor protein S. 
The amount of fibrin is also regulated by the fibrinolytic system. Under 
physiologic conditions, fibrinolysis is initiated when plasminogen is converted 
into plasmin by tissue-type plasminogen activator (t-P~), released from 
endothelial cells, or by activation of pro-urokinase mto urokinase-type 
plasminogen activator (u-PA) or by a still unknown proactivator. Plasmin 
does not only lead to the breakdown of fibrin, but, when present in high 
concentrations in the circulation, it may also lead to the destruction of 
fibrinogen and factor V and VIII. The activity of plasminogen activators is 
regulated by inhibitors (PAl), of which PAI-l, the rapid inhibitor of t-PA, in 
turn may be inhibited by protein Ca. 
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2.3. HEMOSTASIS IN ORTHOTOPIC LIVER TRANSPLANTATION 
2.3.1 THE PREOPERATIVE CONDITION AND HEMOSTATIC PROFILE 
In OLT patients with severe coagulopathy the very high operative blood 
loss appears sometimes to be resistent to massive infusion of plasma or 
plasma products 
parameters that 
order to predict 
(9,26). Some investigators have looked for preoperative 
correlate with the intraoperative use of blood products, m 
which patients are at risk for massive bleeding during 
transplantation and for a high mortality. Patient factors that are known to 
influence intraoperative 
patients it was found 
blood loss are summarized in table 1. In adult OL T 
that the liver's synthetic function, as reflected by 
preoperative coagulation studies, is significantly correlated to intraoperative 
blood loss and survival (9,11,26,27). 
By relating pre-transplantation recipient parameters to intraoperative 
blood loss, Haagsma et al. (11) found that a 24 hr urinary sodium excretion 
:S:10 mmol and serum sodium :S:132 mmol/1 have a 100% predictive value for 
blood loss over 10 l. Blood loss during the operation is also correlated with 
the presence of ascites or low values of antithrombin III, the main inhibitor 
of coagulation. These negative effects 
last to the end of the recipient 
preoperative 
transfusion 
clotting function 
of plasma-products 
(28) have been 
in 
and 
used. 
of the liver disease on hemostasis may 
operation. In attempts to optimize the 
patients undergoing OLT, preoperative 
platelet concentrates (28,29), as well as 
Although these measures were reported plasmapheresis 
to lead to 
examined in 
reduction 
controlled 
of intraoperative blood usage, 
studies. In Pittsburgh we found 
they have not been 
that the total degree 
of coagulation disturbances, measured by a coagulation abnormality score may 
predict intraoperative blood usage and survival in OLT (9). Although a 
comparable correlation was found by others in a limited number of pediatric 
OL T patients (30), the situation in pediatric OLT may be different, since no 
such correlation was found in a larger series of 216 children undergoing OL T 
(31). 
In addition to these reports many authors have concluded that intra-
operative changes in hemostasis and blood loss are strongly associated with 
the diagnosis of the liver disease (5,10,26,32). This is not surprising as the 
magnitude of pre-existing hemostasis disorders, the extent of collateral 
circulation and portal hypertension are factors that vary in severity and 
frequency among the different types of liver disease (15). Liver diseases in 
14 
which parenchymal cells are extensively damaged, such as postnecrotic 
cirrhosis, fulminant hepatitis and a rami trypsin deficiency, are frequently 
accompanied by disorders in coagulation (9,19) and fibrinolysis (21,33). In 
patients with malignancy or when bile ducts are involved (primary biliary 
cirrhosis, sclerosing cholangitis) large areas of normal parenchymal 
still able to produce normal levels of coagulation factors. 
circulation may cause serious operative difficulties and excessive 
during removal of the host liver (2, 10,34). 
tissue are 
Collateral 
blood loss 
Previous abdominal surgery resulting in adhesions has been recognized as 
a risk factor for severe bleeding and a high mortality in adults (2,10,35,36). 
The performance of a routine mini-laparotomy in patients with tumors and 
without cirrhosis for staging purposes, however, was not found to cause 
serious problems by the group in Cambridge (37). In pediatric patients, 
previous surgery may also be associated with a greater blood loss, but the 
mortality rate was found to be similar to children without previous surgery 
(38). Apparently, in pediatric patients who have had previous abdominal 
surgery, mortality depends on other factors than intraoperative blood loss 
alone. 
Table 1. Patient factors influencing intraoperative 
blood loss in liver transplantation 
I. Primary diagnosis 
2. Severity of the liver disease 
3. Preoperative hemostatic disorders 
4. Previous abdominal surgery 
5. Extent of collateral circulation 
6. Presence of ascites 
7. Renal function 
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2.3.2 INTRAOPERATIVE CHANGES IN HEMOSTASIS DURING OLT 
In addition to the preexisting hemostatic disorders, specific intraoperative 
changes in the hemostasis system have been found in OL T. Hemostatic 
changes 
parts of 
that have been described 
the surgical procedure: 
in OL T can be related to three different 
the induction of 
anesthesia until ligation of the patients 
preanhepatic period after 
own liver blood supply, the anhepatic 
period and the postanhepatic period after reperfusion of the liver graft until 
the end of surgery. A hemorrhagic diathesis is most often seen during the 
anhepatic period and in the early postanhepatic period. 
2.3.2.1 The Preanhepatic period 
In the preanhepatic period serious changes in coagulation and fibrinolytic 
activity are usually not found. (32,39,40) The hemostatic profile mainly 
reflects the patient's preoperative hemostatic defects, which are dependent 
on the etiology and severity of the liver disease (9,41). Patients with severe 
liver dysfunction due to extensive loss of functioning hepatocytes (i.e. 
postnecrotic cirrhosis) may at OLT show all the signs of hemostatic distur-
bances that are seen in severe liver cirrhosis (8,11,26). 
Some investigators have reported signs of hypercoagulability, as measured 
by thrombelastography, in the preanhepatic period (42,43). This may be due 
to some activation of the coagulation system by surgical trauma, as can also 
be seen during other types of liver surgery (25,42,44). It is important to 
note that these observations were mainly made in patients undergoing OLT 
for a liver tumor (42). Most of the patients had preoperatively elevated 
levels of fibrinogen and platelet count, which are usually not found in 
patients with a cirrhotic liver. Indeed, in later reports of larger series of 
OLT in patients with severe hepatic dysfunction, early hypercoagulation was 
not found to be a frequent phenomenon (32,39). These patients suffer from 
hypocoaguloability as a result of the reduced synthetic function of the liver, 
rather than hypercoaguloablity. 
Enhanced fibrinolytic activity may be found during this period in 10-
20% of the cirrhotic patients (45,46), but the most important cause of blood 
loss in this period is the removal of the diseased liver and the transection 
of collaterals in the abdomen (8,10,11,34), that are often found in these 
patients. 
2.3.2.2 The Anhepatic Period 
More 
period, 
significant changes in 
which is often associated 
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hemostasis occur 
with increased 
during 
blood 
the anhepatic 
loss. In several 
studies, signs of disseminated intravascular coagulation (DIC) (47-50), 
hyperfibrinolysis (32,39,44,51), or a combination of both have been found 
(52,53). Theoretically, DIC may contribute to bleeding complications by two 
different mechanisms. Firstly, consumption of coagulation factors, due to 
intravascular fibrin formation may lead to extremely low plasma levels of 
these coagulation factors. Secondly, intravascular thrombin formation during 
DIC may cause secondary activation of the fibrinolytic system. Both proces-
ses have been considered to be major causes of hemorrhage during the 
anhepatic period of OLT (41,47,48,52-54). In experimental and clinical 
studies a simultaneous reduction of platelet count, fibrinogen, clotting 
factors II, V, VII, VIII, X and antithrombin Ill has been observed and 
interpreted as signs of DIC (41,48,52-58). Lack of hepatic clearance of 
activated coagulation factors and lack of synthesis of coagulation factors 
and inhibitors during the anhepatic period have been mentioned as factors 
provoking DIC (41,43,54). However, in other studies no clear signs of DIC 
were found and the role of DIC has been disputed (32,59,60). Although some 
authors have reported a beneficial effect of intravenous heparin ( 42,57), 
others could not influence the abnormalities by administration of heparin 
(48,55). Currently, the use of heparin is generally avoided as even small 
amounts of heparin may lead to severe hemorrhage (54). 
It is unlikely that lack of synthesis of coagulation factors really plays a 
role in the abrupt changes observed during the anhepatic period, since 
plasma half-life of most of these proteins is much longer than the duration 
of this period. An intraoperative reduction of plasma levels of fibrinogen and 
antithrombin Ill has also been found during other types of surgery (61,62), 
even in patients that were systemically heparinized (61). Hemodilution by 
saline infusions or unbalanced transfusion of red blood cells and plasma may 
be a cause of reduction of plasma levels of coagulation factors and an intra-
operative decrease of hematocrit may be found in some reports on OLT 
(49,50). This suggests that hemodynamic changes may play a role in the 
intraoperative decrease of hemostasis factors, which is supported by the 
rapid rise in plasma levels of coagulation factors which has sometimes been 
observed a few hours after transplantation. 
In recent reports of large senes of OLT only minor changes in coagu-
lation profiles were described during the anhepatic period (32,39,40,45,63). 
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These observations do not support the theory of DIC m this period 
Increased fibrinolysis, as measured by shortened whole blood clot lysis time, 
time (47,48,44,52) and thrombelastography (32,45) 
found during the anhepatic period in many studies. 
euglobulin clot lysis 
however, has been 
Several authors have speculated that increased fibrinolytic activity is an 
important factor in the origin of hemorrhage ( 45,51 ,57). The presence of an 
active fibrinolytic process has been demonstrated by a simultaneous decrease 
of a 2-antiplasmin, the major inhibitor of plasmin, and of plasminogen activity 
during the anhepatic stage (39,40,57,63). However, it is still a point of 
discussion whether the increased fibrinolytic activity in OLT is the result of 
a primary process or secondary to low grade DIC. In several studies in-
creased fibrinolytic activity has been found without signs of DIC (39,45,51). 
Lewis et al (39,63) observed a disproportionate decrease in factors V and 
VIII:C during periods of hyperfibrinolysis, suggesting that these factors might 
be destroyed selectively by circulating plasmin in the process of active 
fibrinolysis. 
Primary hyperfibrinolysis may result from an impaired balance between 
activators and inhibitors. The most potent plasminogen activator, tissue-
type plasminogen activator (t-PA), is synthesized and released into the 
circulation by endothelial cells (64,65). The liver has been shown to have an 
important function in the rapid clearance of t-PA from the circulation 
(66,67), with a plasma half-life of about three to five minutes (68). In 
recent small studies it was found that t-PA activity reaches a peak at the 
end of the anhepatic period (46,69). Increased plasma levels of t-PA were 
associated with hyperfibrinolysis and high intraoperative blood loss (69). 
Lack of hepatic clearance of plasminogen activators may explain the m-
creased fibrinolysis during the anhepatic period (49,70,71). Support for this 
view has been found in studies of animals undergoing hepatectomy. An 
increased fibrinolytic activity was found in plasma after hepatectomy 
(44,70,72) and after exclusion of the liver from the animal's circulation 
(66,71,72). Furthermore, it has been demonstrated that patients with liver 
cirrhosis are prone to activation of the fibrinolytic system by stimuli that 
cause release of t-PA (33,73). In addition, the plasma half-life of t-PA is 
prolonged in cirrhotic patients, probably due to a diminished hepatic 
clearance (74). 
In general, the assessment whether increased fibrinolytic 
a primary process or secondary to DIC is hampered 
differentiation by laboratory tests (75). Recently, specific 
activity is due to 
by difficulties in 
enzyme immuno-
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assays (ELISA's) have been developed for the separate determination of 
fibrinogen degradation products and fibrin degradation products in plasma 
(76). These assays appear to be promising tools for studies on disturbances 
in the equilibrium of the 
not been used 
coagulation and fibrinolysis (76,77). Although these 
in OLT yet, they may give a better understanding assays have 
of whether 
dary to DIC. 
the observed fibrinolytic activity is of primary origin or secon-
Independent of hemostatic disorders, the use of a venous bypass in the 
anhepatic period may reduce intraoperative blood loss (78). The use of a 
venous bypass has been propagated in order to improve cardiovascular 
stability and decompress the portal venous system during the anhepatic 
phase (79). In Pittsburgh, the use of venous bypass, without systemic 
heparinization, resulted in significantly less blood use during surgery when 
compared with patients in a previous series undergoing OLT without bypass 
(78). However, the methodology of this study does not exclude the possibility 
that other factors including improved surgical techniques, contributed to this 
effect. In some centers a different technique is used (80), whereas others do 
not use hepatic veno-venous bypass in all patients (10,40). Therefore, a 
comparison of different reports is difficult and further reports from rando-
mized controlled studies have to be awaited before definite conclusions can 
be drawn. 
2.3.2.3 The Postanhepatic Period 
Reperfusion of the liver graft is associated with major deteriorations of 
blood coagulation and an increase of fibrinolytic activity. Abnormal bleeding 
is often seen in this period and many studies have been specially designed to 
clarify the mechanisms that are responsible for this hemorrhagic diathesis. 
The processes that may explain the increased bleeding tendency after graft 
reperfusion are summarized in table 2 and will be discussed in more detail 
below. 
Table 2. 
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Processes that may effect hemostatic function 
after graft reperfusion 
a. Disseminated intravascular coagulation (DIC) 
b. Increased fibrinolytic activity 
c. Trapping of platelets 
d. Release of heparin or heparin-like substances 
e. Dilutional effect of preservation fluid 
f. Humoral and metabolic factors 
g. Graft preservation damage 
a) Disseminated intravascular coagulation (DIC) 
During ischemic preservation of a liver, the endothelial lining of the 
blood vessels may become damaged and desquamation of endothelial cells has 
been found in badly preserved livers (81). The injured endothelium and/or 
release of thromboplastic material may lead to platelet aggregation and 
activation of the coagulation system after graft reperfusion (54,82). DIC has 
been proposed by 
hemostatic changes. 
VII, VII, IX and 
several investigators as the explanation of the observed 
A decrease of clotting factors (fibrinogen, factors II, 
X) and of the platelet count and antithrombin III, and 
prolonged clotting times (activated partial thromboplastin time, prothrombin 
time, thrombin time) have been found after graft reperfusion in both clinical 
(44,52-54) and experimental situations (44,48,57,60). 
In man, as in animals, the severity and duration 
malities seems mainly to be related to the quality 
of coagulation abner-
of the donor liver 
(44,52,54). By using 
animals the depression 
directly related to the 
liver grafts after different preservations times in 
of platelets and clotting factors was shown to be 
amount of ischemic damage of the graft (48,59,70,83). 
In experiments where blood samples were taken from both the arterial inflow 
and venous outflow of the recirculated liver graft, an arterio-venous platelet 
gradient was found across the graft (70,84,85). Attempts to counteract this 
phenomenon by the administration of heparin have not been successful (55). 
In recent large series of OL T, DIC was not found to be a major cause of 
excessive bleeding, since only minor changes m clotting factors, suggesting 
this diagnosis, were observed 
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(32,39,63,86). Since histopathological 
demonstration of fibrin depositions are the only objective and definite 
evidence for DIC, some investigators have performed histopathologic studies 
after liver transplantation. In none of these 
demonstrated despite clinical suspicion of DIC 
studies microthrombi could be 
in human (59,87) and animal 
homotransplantation (60,70,84). Improvements in organ procurement and 
of preservation techniques seem to have reduced 
DIC, which were frequently reported m the 
the intraoperative signs 
past. Therefore one may 
conclude that DIC is no longer an important component of the disturbed 
hemostatic function after graft recirculation, provided that the quality of the 
donor liver is good. Other processes are probably responsible for the 
bleeding tendency in this period. 
b) Increased fibrinolytic activity 
Increased fibrinolytic activity is almost invariably found after graft 
recirculation in both clinical and experimental studies. However, there has 
been discussion whether this fibrinolytic activity is of primary origin or 
secondary to DIC, mainly because of difficulties in differentiation by 
laboratory tests. In the initial studies in the sixties, activation of fibrinolysis 
was thought to be predominantly secondary to DIC (48,52). The significance 
of increased fibrinolytic activity in the pathogenesis of hemorrhages was 
later questioned by several investigators (53-56,60,71). In more recent 
publications, a marked increase in fibrinolytic activity, as demonstrated by 
thrombelastography (TEG), was found in 34% of the OLT patients and the 
enhanced fibrinolytic activity was thought to be a primary event and not 
secondary to DIC (45). The endothelium of the liver is an important source 
of plasminogen activators (88) and release of these activators from the 
preserved and ischemically damaged transplanted liver has been suggested as 
an explanation for the increased fibrinolytic activity (44,70-72). Theoretically, 
increased amounts of t-PA may be released from ischernically damaged 
endothelium. Thus far only a limited number of OLTs have been reported in 
which t-PA levels were measured (46,69). In these patients no increase of t-
PA was seen after graft reperfusion, but larger studies have to be awaited 
before definite conclusions can be drawn. Contact activation of the intrinsic 
fibrinolytic 
urokinase 
accelerated 
system (89), activation of protein 
(91) are other mechanisms that 
fibrinolysis after graft reperfusion. 
investigation too. 
C (90) or activation of pro-
may theoretically lead to an 
These processes need further 
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Although in most studies the increased fibrinolytic activity was found to 
be a transient and self-limiting process (44,92), some investigators have tried 
antifibrinolytic treatment. The results of these studies, unfortunately, do not 
seem to allow a uniform conclusion. Some authors reported the prevention of 
primary increased fibrinolytic activity, reduction of blood loss and operative 
mortality in humans and animals following treatment with epsilon-
aminocaproic acid (EACA) or natural antiproteolytic agents (57 ,58,92). 
However, other investigators could not find such positive effects and in some 
OLT cases thromboembolic complications were observed after administration 
of EACA ( 44,48). The different effects may be due to differences in doses of 
EACA and differences in surgical techniques, and the clinical studies 
comprised only small numbers of patients. 
When antifibrinolytics are given to patients with DIC, the balance 
between coagulation and fibrinolysis may be further pushed towards the side 
of increased fibrin formation. Antifibrinolytic agents should be reserved for 
the treatment of uncontrollable oozing where excessive primary fibrinolysis is 
considered likely (93). Using this policy, favorable therapeutic effects of 
antifibrinolytic agents in OLT have been reported by Kang et al. ( 45). In an 
open study administration of a low dose of EACA intravenously (1 g) to 20 
patients who showed active fibrinolysis and generalized oozing, was found to 
have a positive effect on the hemostatic profile when the drug was proven 
effective by thrombelastography of EACA treated blood in vitro. 
The use of antifibrinolytic agents in OLT, however, will remain contro~ 
versial as long as it is not clear whether the increased fibrinolytic activity 
is a primary process or secondary to DIC. Furthermore, objective evidence 
for the effectiveness of antifibrinolytic therapy in reducing blood loss in 
OL T can only be obtained from randomized controlled studies. 
c) Trapping of platelets 
The systemic platelet count often decreases during and after OLT 
(59,94). The drop in platelet count is most dramatic after graft recirculation 
and thrombocytopenia may last for 3-5 days postoperatively (40,59,94). Severe 
thrombocytopenia may contribute to the high incidence of perioperative 
bleeding complications. 
Since the observed thrombocytopenia is not necessarily accompanied with 
a decrease of clotting factors, it cannot be explained as a sign of DIC only. 
Experimental studies suggest a role of the transplanted liver in the origin of 
the thrombocytopenia (43,59,70). By simultaneous measurement of platelets in 
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arterial inflow and venous outflow up to 55% reduction of platelet count was 
found across reperfused liver grafts (70). Infusion of radiolabeled autologous 
platelets in four patients who underwent 
tration of platelets in the transplanted 
formed to elucidate the pathophysiologic 
OLT provided evidence for seques-
liver (94). Histologic studies per-
mechanisms of this fall in platelet 
count have not provided a uniform explanation. Hutchinson et al. (59) were 
unable to demonstrate intravascular coagulation as a cause of reduction of 
platelets. They instead found evidence for the extravasation of platelets into 
the spaces of Disse in many of the homografts biopsied shortly after 
transplantation in dogs. However, others have not confirmed these observa-
tions. 
Increased phagocytosis of platelets by Kupffer cells of the transplant has 
also been suggested to explain the thrombocytopenia after OLT (95). Other 
investigators found changes of platelet function to be of greater importance 
than changes in platelet number, giving transient prolongation of the 
bleeding time in dogs after OLT, while platelet counts remained in the low 
normal range (96). These authors suggested a process of reversible platelet 
aggregation in association with an activation of the reticulo-endothelial 
system after graft recirculation, later 
tioning platelets into the circulation 
donor liver plays an important role 
followed by a release of nonfunc-
(96). Although it is likely that the 
in the decreased platelet count found 
after OLT, the underlying mechanism remains unsolved. 
d) Heparin or heparin-like substances 
Stremple et aL (60) have postulated that hemostatic dysfunction after 
graft recirculation may be caused by a release of heparin or heparin-like 
substances. Much evidence for the release of a heparin-like substance has 
been obtained from animal experiments (57,60,70). In these studies, an 
isolated prolongation of the partial thromboplastin time or thrombin time, 
that could be partially neutralized with protamine sulfate, was observed 
after graft recirculation. Dogs especially are highly vulnerable to release of 
these substances during periods of shock or acute phase reactions (97 ,98). 
Therefore, these observations do not necessarily apply to humans. An 
anticoagulant effect may also be produced by fibrinogen degradation products 
(47), and it has not always been possible to differentiate these substances 
from heparin. 
The first clinical OLTs were performed with heparin in the preservation 
fluid or administered to the donor or recipient. In this situation it was 
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difficult to estimate whether release of endogenous heparin (-like substance) 
played an important role in the diminished coagulability found after recircu-
lation. Later it was noticed that the use of exogenous heparin promotes 
bleeding (54). The complete absence of clotting activity observed in the first 
clinical OLTs was probably partially due to use of heparin in the preser-
vation fluid, in combination with systemic heparinization of the recipient. 
Heparin in the preservation fluid may become sequestered in the hepatic 
graft during preservation and enter the circulation after reperfusion 
(54,86,99). Heparin tolerance is greatly diminished in the recipient at the end 
of the operation and the capacity to eliminate exogenous heparin is often 
reduced or nearly lost. The avoidance of excess circulating heparin has been 
strongly recommended (54). Although systemic heparinization of the recipient 
use a is no longer performed as a standard procedure, and most centers 
preservation fluid without heparin, a "heparin effect" may still be seen 
graft recirculation in some patients. This can be easily treated with 
tamine sulphate and suggests that release of endogenous heparin 
substances) may play a role in the bleeding tendency in some patients 
Kang 1988, personal communication). 
e) Dilutional effect of preservation fluid 
after 
pro-
( -like 
(YG 
Influx of organ preservation solution from 
suggested to dilute coagulation factors (32). This 
the donor liver has been 
may be 
tion for the decrease in coagulation factors if histological 
the main explaina-
evidence for D I C 
is absent. From analysis of studies that included measurement of hematocrit 
it appears that a decrease of coagulation factors often parallels the decrease 
of hematocrit (49,50). If this dilution is not taken into account an unjus-
tified diagnosis of DIC may be made, which may explain the overestimation 
of the occurrence of DIC in some early studies. 
f) Humoral and metabolic factors 
Metabolic acidosis, decrease in cardiovascular performance (100, 101), 
decrease in plasma ionized calcium level (I 02), decrease in body temperature 
(103) and hyperkalemia (100,101) have been observed during OLT. Since all of 
these can adversely affect the hemostatic system, the role of humoral and 
metabolic factors in the occurrence of hemostatic disorders after graft 
recirculation has been emphasized. In a large clinical study, in some patients 
blood coagulability, as measured by TEO, improved without significant 
changes in plasma levels of coagulation factors occuring but coinciding with 
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the recovery of the above metabolic abnormalities about 30 min after graft 
recirculation (32). The effect of changes in plasma electrolytes and metabolic 
factors on hemostasis in OLT has received little attention and more investi-
gations on this subject are warranted. 
g) Preservation damage 
The importance of preservation damage to the donor liver in deteriora-
tion of hemostasis has been emphasized by several investigators 
(47,52,55,70,71,83,92). In animal, transplantation of livers preserved for 24 
hours invariably led to severe and lasting depression of platelets and 
clotting factors and almost all animals died of uncontrollable bleeding 
(48,55). Experiments with auxiliary heterotopic transplantation of livers 
preserved for 24 hours provided direct evidence that the systemic changes 
in coagulation are at least partly due to events occurring in the damaged 
graft and not only to loss of the clearance and synthesizing function of the 
damaged liver graft (70,84,85). Marked hypocoagulopathy occurred both in 
pigs that had received an orthotopic transplant and those with an auxiliary 
heterotopic transplant. The only difference between the two groups was that 
orthotopically transplanted animals developed in addition a very marked 
increase in fibrinolysis whereas the heterotopic group did not (70,84,85). 
Although contact activation of blood by the injured endothelium and/or 
release of materials with thromboplastic activity were suggested to be 
responsible for the arterio-venous gradients of platelets and clotting factors 
across the auxiliary grafts, no attempt was made to have this confirmed by 
histopathological examination. In contrast to the changes seen in coagulation, 
the diminished clearing function of the damaged graft undoubtedly 
contributes to the increased fibrinolytic activity. Heterotopic transplantation 
of 24 hrs-preserved livers had no systemic effect on fibrinolysis, whereas 
orthotopic transplantation caused a marked shortening of the euglobulin lysis 
time in pigs (70,84,85). These studies confirm that hemostatic disorders may 
result from reperfusion of badly preserved liver grafts. Optimal graft 
preservation has 
disturbances of 
been shown to be of utmost importance in preventing major 
the hemostatic balance (55,70,83,92). The development of 
better graft preservation techniques will probably further improve the 
success rate of OLT (3). Hopefully, better graft preservation will also con-
tribute to a more stable hemostatic level and less bleeding complications 
after graft recirculation. 
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2.3.3 INTRAOPERATIVE MONITORING AND CORRECTION OF HEMOSTASIS 
DEFECTS 
A difficulty in the intraoperative management of OLT has been in the 
monitoring of both the coagulation and fibrinolytic system. Since disorders in 
hemostasis during OLT often occur acutely and may become serious in a 
short time, close and rapid monitoring is necessary (104). The number and 
choice of hemostasis tests that are used intraoperatively varies somewhat 
from center to center (105). Some centers only perform conventional clotting 
assays, while others also include assays for individual clotting factors and 
euglobulin lysis time. However, as long as the exact mechanism underlying 
the hemostatic abnormalities in OL T are not understood, there are no clear 
indications for the use of any specific test. 
Thrombelastography (TEG), a method by which both fibrin formation and 
fibrinolysis can be monitored, (106) has been proposed as an overall 
measurement of the complete hemostasis process (42,44). Some centers have 
included TEO or SonoclotR, a comparable instrument, in their monitoring 
scheme. The clinical effectiveness of TEO in guiding replacement therapy 
has been demonstrated by Kang et al. (32). The required volume of fluid 
infusion decreased by 
OLT. These results 
33% after the introduction of TEO monitoring during 
can be criticized since the effect of TEO was not 
demonstrated in a randomized study and a historical control group was used. 
Improved surgical techniques and the use of venous bypass in all but two 
patients in the TEO-monitored group, but not in the control group, may 
have contributed to the differences between the two groups. A beneficial 
role of TEG monitoring has also been suggested by others (107), although 
randomized studies have not been reported. An important advantage of TEG 
may be the earlier detection of increased fibrinolytic activity than is 
possible with ordinary laboratory methods ( 42, I 08). In a renewed attempt to 
combat enhanced fibrinolytic activity during OLT in Pittsburgh, TEG was 
found to be promising in guiding antifibrinolytic treatment (45). 
Differences m methods, large variations in the amounts of transfused 
blood products, variations in the selection of patients for OLT and small 
numbers of patients in some studies have made it difficult to compare the 
results of different monitoring strategies. Recently, the National Institute of 
Health started to establish a liver transplant data base by pooling informa-
tion from five liver transplant centers in the U.S.A. This includes the results 
of ll hemostasis tests at 10 points during and after OLT. It is hoped that 
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this study will provide more information on which hemostasis tests are useful 
to guide replacement of blood products during OLT (105). 
2.4. HEMOSTASIS IN AUXILIARY LIVER TRANSPLANTATION 
Auxiliary transplantation of a liver graft in a heterotopic position is an 
alternative method of liver transplantation, with the theoretical advantage of 
leaving the host liver in situ (109,110). As pointed out above, many of the 
bleeding problems and hemostatic disturbances in OLT are related to the 
anhepatic phase. In auxiliary 
and blood consuming removal 
anhepatic phase and serious 
heterotopic liver 
of a cirrhotic 
transplantation the 
liver with the 
hemostatic disorders is avoided. 
laborious 
subsequent 
Therefore, 
changes in hemostasis may be less prominent, but information on this subject 
is limited. Only a small number of auxiliary liver transplantations have been 
performed in humans (109) since the first report in 1964 (Ill). A further 
application of this technique was held up by the discouraging results: most 
patients died within one month. Recently, however, many of the technical 
problems of this technique seem to have been resolved by improving the 
surgical procedure and the transplantation of a partial graft (112,113). This 
improved technique of auxiliary partial liver transplantation (APLT) is now 
performed in Rotterdam in patients with acute fulminant hepatic failure, or 
with end-stage chronic liver disease who have been rejected for OLT because 
of poor physical condition (114,115). 
Sparse information on the influence of APLT on hemostasis was obtained 
from the initial animal studies in the sixties and seventies (60,70,85). In most 
of these studies heterotopic auxiliary liver transplantation was used to 
examine the effect on the hemostasis system of graft damage after long-term 
preservation (70,85). In addition, the studies were performed during a periOO 
when heparin was generally used, both systemically in the recipient and in 
the preservation fluid. Only a few experimental studies (60) and some case 
reports in humans (42,59,99) on the changes in hemostasis during and after 
transplantation of better-preserved auxiliary livers grafts were published in 
the sixties and seventies. The results of the first 8 APLTs in Rotterdam 
were published recently ( 116, 117). In these patients and in the earlier studies 
it appears that important changes in hemostasis are first observed after 
recirculation of the auxiliary graft and that these resemble the changes that 
are seen after graft reperfusion in OLT. Most of these hemostatic changes 
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have been described above. An acute drop of platelet count has been seen 
after recirculation, probably due to sequestration in the auxiliary graft (59). 
In animal studies, release of heparin-like factors from the livers was seen 
(60,70). A major difference with OLT seems to be the lack of markedly 
increased fibrinolytic activity, which can be explained by the remnant 
clearing function of the host liver (50,70,85, !!6). Even after heterotopic 
transplantation of an auxiliary liver in pigs with fulminant hepatic failure, 
no activation of fibrinolysis was detected by TEO (!!8). As mentioned 
earlier, other factors including preservation damage have hampered inter-
pretation of some of the earlier experimental studies. Furthermore, experien-
ces with APLT in humans are still limited. Therefore, definite conclusions 
cannot be drawn and new studies are necessary to investigate the influence 
of APLT on hemostasis and compare APLT with OLT. 
Whether pre-existing hemostatic disorders are less hazardous m APLT 
and whether the advantage of not removing the host liver lead to increased 
survival in high risk patients undergoing OLT, can only be answered from 
further clinical experience. 
2.5. CONCLUDING REMARKS 
The magnitude of bleeding during orthotopic liver transplantation (OLT) 
appears to result from two factors: poor preoperative hemostatic capacity, 
complicated by specific intraoperative deteriorations, and the 
difficulties of the surgical procedure. Preoperative hemostasis 
correlate with the underlying liver disease, intraoperative blood 
mortality. Improvement of hemostatic function by substitution is 
technical 
parameters 
loss and 
therefore 
an important aspect of the preoperative management. Blood loss during the 
preanhepatic phase of the operation is mainly of surgical origin. In cirrhotic 
patients with portal hypertension, bleeding occurring during the transsection 
of the collateral circulation may be aggravated by a poor hemostatic 
function, secondary to the underlying liver disease. The hemorrhagic 
diathesis during the anhepatic and postanhepatic period has been explained 
by the occurrence of DIC, hyperfibrinolysis or a combination of these 
processes. Most of the evidence for the role of DIC in uncontrollable 
bleeding dates form studies in the sixties and seventies. Since then, improve-
ments in surgical and anesthesiologic techniques, and more stringent intra-
operative substitution therapy may have contributed to the prevention of 
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DIC. In recent large studies no important signs of DIC were found during 
the anhepatic period. Histologic studies of biopsies of the liver graft taken 
at different intervals after reperfusion have also never provided convincing 
evidence for the intravascular fonnation of microthrombi or platelet aggre-
gates. Signs of increased fibrinolytic activity, however, 
found during OLT. This hyperfibrinolysis is probably due 
increased release and reduced hepatic clearance of 
are still frequently 
to a combination of 
t-PA, resulting in 
increased plasma levels of t-PA. After graft recirculation, restoration of the 
hemostatic balance is largely dependent on the quality of the liver graft. 
Optimal graft preservation has been found to be of paramount importance m 
the prevention of intraoperative hemostatic deterioration. 
For intraoperative patient care a bedside monitoring system, such as 
thrombelastography, in combination with specific hemostasis tests, including 
the prothrombin time, activated partial thromboplastin time, thrombin time, 
fibrinogen, euglobulin clot lysis time and platelet count is a minimal requi-
site. Hemostasis tests should be performed at intervals of 0.5 - 2 hours, 
depending on the stage of the surgical procedure. Frequent testing is 
especially advised during the first two hours after graft reperfusion. 
Prolonged coagulation times should be treated with fresh frozen plasma. 
Cryoprecipitate is indicated when fibrinogen levels are low, and platelet 
concentrates should be available to treat severe thrombocytopenia. In 
patients with marked blood loss, in whom primary hyperfibrinolysis is likely, 
antifibrinolytic therapy (EACA, Tranexamic acid) may be beneficial in 
treating life-threatening hemorrhage. 
of hemostatic deteriorations in Further investigations on the etiology 
OLT and application of recent developed 
give better insight into the mechanisms 
specific and sensitive assays may 
underlying the hemostatic disorders 
bases for improved treatment. To in OLT, and provide new theoretical 
obtain objective evidence whether 
reduction of intraoperative blood 
standard surgical and anesthetic 
performed. Hopefully this will lead 
a new therapeutic procedure leads to a 
loss, randomized clinical studies, using 
methods in all patients, should be 
to a further reduction in usage of blood 
products during liver transplantation in the future. 
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SUMMARY 
We compared the effects of orthotopic liver transplantation (OLT) (group 
A, n=l2) and auxiliary, heterotopic partial liver transplantation (APLT) 
(group B, n=ll) in pigs, on blood loss and on the hemostasis system. Blood 
samples were taken at regular intervals during and after the operations. In 
both groups nine animals survived longer than 24 hrs and data from these 
animals were used for analysis. Intraoperative blood loss in OLT was 850.0 ± 
23.1 ml and in APLT 437.5 ± 12.9 ml (mean ± SD; p<O.Ol). Routine clotting 
times, such as the activated partial thromboplastin time, prothrombin time 
and thrombin time showed no major intraoperative changes in both groups. 
Fibrinogen levels decreased in both groups, but no significant differences 
were found between the two groups. The only significant difference between 
group A and B was a more sustained increase in fibrinolytic activity after 
graft recirculation in group A. Postoperatively, restoration of fibrinogen, AT+ 
III and o:rantiplasmin levels was slightly faster in group B, resulting m 
significant higher levels at the first day postoperatively. We conclude that, 
in this animal model, APLT is associated with significant lower blood loss 
and less severe fibrinolytic activity, compared with OLT. This difference 
might result from the lack of an anhepatic period and the reduced surgical 
trauma in auxiliary, heterotopic liver transplantation. 
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INTRODUCTION 
Although orthotopic liver transplantation (OLT) has become an accepted 
method to treat patients with an end-stage of chronic liver disease, it is 
still associated with massive intraoperative blood loss and the use of large 
amounts of blood products (1,2). Excessive blood loss is associated with an 
increased perioperative mortality and morbidity (3). Massive transfusion of 
blood products 
transplantation (3). 
Bleeding of 
also contributes 
surgical 
hemostatic deteriorations, 
origin 
which 
significantly to the total costs of liver 
may be seriously complicated by specific 
occur especially during the anhepatic and 
post-anhepatic periods (2,4). Disseminated intravascular coagulation (DIC), 
primary increased fibrinolysis, or a combination of both processes has been 
suggested as a major cause of bleeding in orthotopic liver transplantation ( 4-
9). Lack of hepatic clearance of activated coagulation factors or activators 
of the fibrinolytic system may lead to the severe disturbances of the 
hemostasis system in the anhepatic phase of OLT (7,8). Auxiliary, hetero-
topic liver transplantation has been proposed as an alternative to hepatic 
replacement. The main theoretical advantage of auxiliary liver transplantation 
is avoidance of the technical hazards of recipient hepatectomy and the lack 
of an anhepatic period (10,11). A second advantage may be that the recipient 
is not at the outset totally dependent on the function of the homograft. 
These differences might attribute to less severe hemostatic disorders and the 
usage of smaller amounts of blood products. However, information on this 
technique and its effect on hemostasis is limited. Only a small number of 
auxiliary liver transplantations have been performed in humans in the past 
(10,12). The initial discouraging results have held up further application of 
this technique. Recently many of the technical problems seem to be resolved 
by improving the procedure and by using a partial graft (13,14). The first 
clinical applications suggest that this improved technique of auxiliary partial 
liver transplantation (APLT) may be performed successfully without serious 
changes in blood coagulation and fibrinolysis, even in patients with poor 
preoperative hemostatic function (15-17). However, objective information on 
the advantages and disadvantages of both techniques of liver transplantation 
can only be obtained from studies in which both techniques are evaluated 
under identical conditions. 
Therefore, we started a comparative study on orthotopic and auxiliary 
partial liver transplantation in pigs. In this paper we report on the changes 
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in the hemostatic system. Results of differences in surgical and anesthetic 
management will be described elsewhere. 
MATERIALS AND METHODS 
Twenty-three female Yorkshire pigs 
animals were randomly allocated to two 
received an orthotopic liver transplant 
animals that underwent auxiliary partial 
were used m the experiments. The 
groups: animals in group A (n=l2) 
and group B (n=ll) consisted of 
liver transplantation. The donor and 
recipient were matched according to a negative reaction in the mixed 
lymphocyte culture test (MLC) (18). 
All operations were carried out under general anesthesia and the animals 
were ventilated using a Siemens 900 B Servo ventilator. During the opera-
tions Ringers solution, 0.9% NaCI and HaemaccelR were given for hemody-
namic support as needed. Depending on the amount of bloodless, 1-2 U 
donor blood was given in the period after graft recirculation. 
Donor hepatectomy was perfonned using a conventional technique. After 
harvesting, the donor liver was perfused ex-vivo by portal vein cannulation 
with one liter Euro-Collins (4°C) and grafted within 4 hrs. Details of the 
surgical technique relevant to this study are given below. 
Orthotopic liver transplantation (OLT). 
In group A, OL T was performed by standard procedure ( 19). During the 
anhepatic period blood flow from the operative area and the inferior part 
of the body was shunted away by a bypass from the portal and femoral vein 
to the jugular vein, using a heparin-coated extracorporeal circuit (20). No 
systemic heparin was given. 
Heterotopic, auxiliary liver transplantation (APLT). 
In group B an auxiliary transplantation was performed by using a partial 
liver graft. During bench surgery the left medial and lateral lobes of the 
liver were resected as described previously (13). The partial graft, consisting 
of 62% of the donor liver, was placed m the right subhepatic space, anasto-
mosing the suprahepatic vena cava of the graft end-to-side to the infra-
hepatic vena cava of the recipient. The donor portal vein was anastomosed 
end-to-side to the recipient portal vein and an end-to-side anastomosis was 
made between the graft hepatic artery to the recipient's infrarenal aorta. 
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Bile flow was reconstituted by a choledochoduodenostomy. In this type of 
liver transplantation no shunt is necessary for the decompression of the 
splanchnic circulation during portal clamping. None of the animals received 
systemic heparin. No immunosuppressive drugs were given in both groups. 
Blood loss and blood sampling. 
Blood loss was quantified by measuring the amount of blood sucked away 
from the surgical field, and collected in Buleaux-bottles during the operation. 
Intraoperatively, blood samples (20ml) were taken from an arterial line, 
while in the post operative period blood was collected from a central venous 
line or by puncturing of the jugular vein. Eighteen ml of blood was divided 
into two polystyrene test tubes, containing ml ice-cold trisodium citrate 
0.11 mol/1 (9vol+lvol) and immediately placed on melting ice. Plasma was 
collected after centrifugation (2800 g, 4°C, 30 min), snap-frozen and stored 
in small aliquots at -70°C until used. Two ml blood was also collected into 
0.045 ml 15% sol6.75 mg EDTA. 
In both groups preoperative blood samples were taken direct after induc-
tion of anaesthesia. The other blood samples were taken 5 min after 
anastomosis of the portal vein (recirculation of the graft), 5 min after 
anastomosis of the hepatic artery, 2 hr and 3 hr after transplantation and 
on postoperative day !, 2, 7, 10, 14, 21, 28 and 35. In group A (OLT), one 
extra blood sample was taken 10 min before the end of the an hepatic phase. 
Biochemical measurements. 
Graft function was monitored by determination of the levels of ASAT and 
bilirubin by standard laboratory techniques. Of each blood sample hematocrit 
was measured to detect possible dilution effects. 
Hemostasis studies. 
Coagulation. 
The activated 
and thrombin 
partial thromboplastin time 
time (ThT) were measured 
Thrombelastography (TEG) was performed in 
(APTT), prothrombin time (PT) 
as described previously (21). 
citrated plasma (22). The r-
value was defined as the time interval between the start of the registration 
and the first deflection on the TEG recording. The k-value was defined as 
the time interval after the first deflection until an amplitude of 10 mm was 
reached. The maximum amplitude (MA) represented the maximum deflection 
on the TEG recording. Fibrinogen was measured according to Clauss (23) and 
antithrombin-III (AT-III) 
al (24). The vitamin K 
N orrnotestR, according 
Diagnostica, Oslo, Norway). 
Fibrinolysis. 
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activity was assayed as described by Abildgaard et 
dependent factors II, VII and X were determined by 
to instructions of the manufacturer (Nyegaard 
To determine the euglobulin clot lysis time (ECLT), standard euglobulin 
fractions of plasma were prepared at pH 5.9 with a plasma dilution of 1:10 
(25). Precipitates were redissolved in Tris(I'ween buffer (0.1 M Tris/HCl, 
containing 0.1% Tween 80 (v/v) pH 7 .5) and to 0.2 ml aliquots of the 
dissolved euglobulin fractions 0.1 ml portions of calcium thrombin solution 
(CaC12 25 mmol/1 and thrombin 10 NIH U/1) were added to induce clot 
formation. The lysis time of the clot was recorded. The disappearance of air 
bubbles was regarded as the endpoint of lysis. a 2-Antiplasmin (az-AP) 
activity was measured according to Friberger et al (26). Plasminogen was 
assayed m acidified plasma using Urokinase (Choay, Paris, France) for 
activation of plasminogen and S-2251 (Kabi Vitrum Haematology BV, Amster-
dam, The Netherlands) as a substrate (27). 
Statistical Analysis. 
Statistical analysis was performed using the Wilcoxon signed rank test for 
paired data and the two-sample test for unpaired data. Values for p<0.05 
were considered to be significant. 
RESULTS 
In both groups nine animals survived longer than 24 hr after transplan-
tation and the data of these animals were used for analysis. In table 1 body 
weight and blood loss in group A (OLT) and group B (APLT) are compared. 
Mean intraoperative bloodloss in group A (OLT) was about twice as high as 
in group B (APLT) (p<0.01). Survival and causes of death in both groups are 
shown in table 2. None of the animals died of postoperative hemorrhage. The 
main causes of early mortality were secondary to surgery and included 
intestinal strangulations. 
Table 1. 
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Body weight and intraoperative blood loss in pigs that under-
went orthotopic (OLT) and auxiliary (APLT) liver transplan-
tation 
Group A Group B 
OLT (n=9) APLT (n=9) p-value 
Bodyweight (kg) 
Blood loss (ml) 
24.9 ± 1.8 
850.0 ± 23.2 
23.4 ± 2.1 NS 
437.5 ± 12.9 p<0.01 
95% confidence limits 
(834.6- 865.4) (428.9- 446.1) 
Results are mean ± SD 
Table 2. 
Pig No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
Survival and causes of death after orthotopic (OLT) and 
auxiliary partial (APLT) liver transplantation 
Group A (OLT) Group B (APLT) 
Survival Cause of death Survival 
(days) 
Cause of death 
(days) 
7 
17 
2 
94 
72 
33 
25 
5 
38 
rejection 
cholangitis 
unclear 
sacrificed in good health 
sacrificed, leg abscess 
unclear 
cholangitis 
volvulus of jejunum 
bile leakage 
35 
8 
15 
50 
86 
91 
159 
93 
23 
sacrificed in good health 
volvulus of jejunum 
volvulus of jejunum 
sacrificed in good health 
sacrificed in good health 
strangulated hernia 
sacrificed in good health 
sacrificed in good health 
purulent pneumonia 
48 
Biochemical measurements 
Liver function and cellular damage, as characterized by bilirubin and 
ASAT levels are depicted in figure 1. In group B (APLT) only minimal 
changes in bilirubin and ASAT were found. OLT (group A) was associated 
with higher levels of ASAT at 3 hrs after transplantation (p<0.05) and a 
maximum was found at the first and second postoperative day. Bilirubin 
levels were also higher after OLT (group A) (p<O.Ol), reaching a peak at 
the end of the first week. 
• 
Bilirubin 
umol/1 
ASAT 
U/1 
Fig. 1. 
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Bilirubin and ASA T levels (mean±SEM) in animals that underwent 
OLT (group A, 0-0) and APLT (group B, ..._. ). * p<0.05, ** 
p<O.Ol, comparison between group A and B. 
Coagulation 
Intraoperatively, none of the investigated coagulation parameters was 
different between the two groups. A rather stable course of APTT and PT 
was found in both groups (figure 2A), as was also found for ThT and NT. In 
fact, the only coagulation parameter which showed important changes during 
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the operations was fibrinogen. A more than 40% decrease of the mean 
fibrinogen levels was found during the operation in both groups (figure 2B). 
This was also reflected by a prolongation of the k-value and a decrease of 
the MA on the TEO-recordings (figure 2A). These changes could not be 
explained by 
found (figure 
hemodilution since no important changes 
2B). A slowly decreasing pattern was also 
platelet count (figure 2B). 
Fibrinolysis 
in hematocrit were 
seen for AT-III and 
Important intraoperative changes were found in the investigated fibrino-
lytic parameters in both groups. Hyperfibrinolysis, as characterized by 
shortened ECLTs and reduction of a2-AP and plasminogen concentrations, 
was found 5 min after graft reperfusion in both OLT and APLT (figure 3). 
During OLT an increased fibrinolytic activity, as measured by ECLT, was 
already present during the anhepatic period. In group A (OLT) a further 
increase of fibrinolytic activity was seen during the post- reperfusion 
period, resulting in significant shorter ECL Ts at the time of completion of 
the arterial anastomosis, compared with group B (APL T) (p<0.05). In both 
groups, ECLT became normal (>180 sec) at 3 hrs after the operation. At this 
time plasma levels of plasminogen and a 2-AP were still reduced. Although 
restoration of cx2-AP levels was apparently faster in group B (APLT) this 
difference was not statistically different. 
Long· term postoperative changes 
In both groups, a recovery of the hemostatic parameters was observed 
during the first postoperative week. There were no differences in APTT, PT 
and NT. Fibrinogen, AT-III and cx2-AP levels at the first day after surgery 
were higher in group B (APLT) (p<O.Ol) (figure 4). Fibrinogen levels showed 
a peak at day 2 in group A (OLT) and at day I and 2 in group B (APLT) 
(figure 4). Platelet count reduced further during the first postoperative days, 
reaching a nadir at the second day m both groups. Thereafter a rapid 
recovery of platelet count was observed, resulting in a thrombocytosis (mean 
values higher than 500x 109 !1) at the end of the first week (figure 4). 
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4 5 
APTT, PT, r-value, k-value and maximum amplitude (MA) of 
thrombelastogram m animals that underwent OLT (group A, 0-0) 
and APLT (group B, ._. ) (mean±SEM). 0 = preoperative; 1 end 
anhepatic phase in OLT; 2 = 5 min after recirculation; 3 5 rmn 
after hepatic artery anastomosis; 4 = 2hr postoperative; 5 3hr 
postoperative. 
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4 5 
Fibrinogen, AT-III, platelet count and hematocrit (Ht) in animals 
that underwent OLT (group A, 0--0) and APLT (group B, ..._. ) 
(mean±SEM). * p<O.OS, comparison between group A and B. 
Legends as in fig. 2A. 
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ECLT, plasminogen and arantiplasmin (arAP) in animals that 
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DISCUSSION 
The anhepatic phase in OLT is associated with serious changes in hemo-
stasis, which may further complicate surgical bleeding and attribute to the 
need of massive blood transfusions (4,9). Auxiliary liver transplantation has 
potential benefits over OLT, as the technical hazards of the recipient 
hepatectomy and the subsequent anhepatic period are avoided. Therefore, 
auxiliary liver transplantation may theoretically be associated with less 
severe hemostatic deteriorations and it may be an attractive alternative for 
OLT. However, objective evidence on the potential advantages of auxiliary 
liver transplantation, regarding blood loss and disturbances of hemostasis are 
lacking. Although a comparison of orthotopic and auxiliary liver trans-
plantation has been made in one earlier study, this was primarily designed to 
study the effect of graft preservation damage on hemostasis and insight in 
the specific changes due to the auxiliary transplantation procedure cannot be 
obtained from this study (28). 
In the present study we investigated the effect on hemostasis of ortho-
topic and auxiliary partial liver transplantation, using techniques which are 
currently used in humans. Both types of liver transplantation were performed 
in a controlled study m healthy pigs. Hereby, the effect of preexisting 
differences in coagulation defects, as may be found in liver patients, were 
avoided. This made it possible to study the specific changes in hemostasis 
due to the surgical procedures only. 
An important difference between OLT and APLT, found in this study, was 
a lower blood loss in the animals that underwent APLT. This is in accor-
dance with our experience in clinical APLT (17). When comparing the 
hemostatic profile of the two groups, differences were not found in the 
blood coagulation system, but rather m the fibrinolytic system. In fact, 
both groups showed only minor changes in the routine clotting rimes. The 
only coagulation parameter that showed serious alterations was fibrinogen. 
A decrease of fibrinogen levels and subsequent prolongation of k-value, 
representing clot formation rate, and a decrease in the MA-value, represen-
ting clot stiffness, on TEO-recordings was found in both OLT and APLT. 
Although the intraoperative decrease of fibrinogen was apparently more 
severe in OLT, this difference was not statistically significant. However, an 
ongoing postoperative decrease of fibrinogen after OLT did result in 
significant lower levels compared with the APLT group at 3 hrs after the 
operation. Several investigators have described a reduction of fibrinogen 
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levels in experimental and clinical OLT (4-9,29). 
tion, disseminated intravascular 
fibrinogenolysis and the effect 
coagulation (DIC), 
of hemodilution 
Mechanisms of consump-
trapping in the graft, 
have been suggested to 
explain this phenomenon (4,9,29). We did not find convincing evidence for 
DIC, and/or hemodilution. AT-III levels never reached extreme low values 
and no serious changes in any of the clotting times and hematocrit were 
observed. The decrease of fibrinogen is most probably caused by a local 
consumption around the surgical wounds. 
We also found signs of hyperfibrinolysis, as characterized by a shortened 
ECLT and decrease of plasminogen and aTantiplasmin levels after graft 
recirculation in both groups. However, fibrinolytic activity was more severe 
and lasted longer in animals that underwent OL T. After recirculation of 
auxiliary grafts, the ECLT showed a fast normalization, and ECLT was less 
diturbed in this group at the time of completion of the hepatic artery 
anastomosis. Many investigators have stressed the role of hyperfibrinolysis in 
the origin of bleeding complications in OLT. Recent studies in clinical OLT 
suggested that increased fibrinolytic activity is predominantly of primary 
origin (9,29) and may result from a combination of reduced hepatic clearance 
and an increased release of tissue~type plasminogen activator (30). The lack 
of an anhepatic phase and the remnant clearing function of the host liver 
might explain why we observed less severe fibrinolytic activation in APLT. In 
agreement with this, we recently demonstrated in a clinical study that signs 
of hyperfibrinolysis are only found in a minority of patients undergoing 
APLT (16). Although the clinical relevance of hyperfibrinolysis in liver 
transplantation is still a point of discussion, this may be an important 
difference between OLT and APLT, and it may attribute to less frequent 
bleeding complications in APLT. 
Another difference between OLT and APLT, found in this study, was an 
earlier restoration of some hemostasis parameters after the operation. 
Levels of fibrinogen, arantiplasmin and AT~III were significantly higher in 
the APLT group at the first postoperative day. Although this study was 
performed in healthy animals and it cannot be deduced whether this effect 
is not predominantly due to synthesis by the host liver, we have observed 
an similar fast restoration of a 2-antiplasmin and AT -III levels in a cirrhotic 
patient with severe preoperative coagulation defects, who underwent APL T 
(16). Postoperatively, we observed a further decrease of platelet count in 
both groups. This is in agreement with clinical findings (5), but the mecha-
nisms underlying this drop of the platelet count are still not clear and are 
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the subject of further research. The thrombocytosis, observed in both groups 
after the first week, can be ascribed to a reactively increased thrombo-
poiesis. Rebound thrombocytosis occurs because of a lag in the feedback 
mechanism associated with the platelet/megakaryocyte control mechanism 
(31 ). 
severe 
tively. 
In cirrhotic patients undergoing liver transplantation 
thrombocytopenia due to splenomegaly is usually 
This may explain why such a thrombocytosis is 
successful clinical liver transplantations. 
a moderate to 
present preopera-
less striking after 
In conclusion, in comparing OLT and APLT in a controlled study, we 
observed a halving of intraoperative blood loss in animals that underwent 
APLT. No differences in the investigated coagulation parameters were found 
between the two groups. Although an increase in fibrinolytic activity was 
found during both types of liver transplantation, signs of hyperfibrinolysis 
were present during a longer period after graft recirculation in OL T. 
Postoperatively, an earlier normalization of disturbed hemostatic parameters 
was seen after APLT. The lack of an anhepatic period in APLT and a 
remnant synthesis and clearing function of the host liver in APLT may 
explain these differences. A controlled study in humans is necessary to 
investigate whether APLT is an good alternative for OLT m severely 
diseased liver patients. 
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SUMMARY 
We investigated the role of the donor liver in the origin of thrombo-
cytopenia and hemostatic disorders in liver transplantation. Eighteen pigs 
received an orthotopic or an auxiliary, heterotopic liver graft. Liver biopsies 
were taken for electron microscopic studies 5-10 min after reperfusion in 
nine animals. Blood samples were taken from the first hepatic outflow and 
from the systemic circulation before and 5 min after graft recirculation. 
Electron microscopy did not show any evidence of microthrombi or platelet 
aggregation in the graft, neither after orthotopic liver transplantation nor 
after auxiliary liver transplantation. Most blood platelets were lying free in 
the sinusoids. They showed cell processes and many of them seemed to have 
lost their granulae. There were also signs of phagocytosis of platelets by the 
Kupffer cells. In the hepatic outflow, platelet count was significantly lower 
and fibrinolytic activity significantly higher, compared with the systemic 
post-reperfusion values (p<O.Ol). There were no important changes in the 
coagulation parameters. No significant changes were found between the 
effects on hemostasis of orthotopic and auxiliary graft reperfusion. This 
study suggests that thrombocytopenia and increased fibrinolytic activity after 
graft recirculation in liver transplantation are not a result of intravascular 
coagulation. Sequestration of platelets in the graft is probably caused by a 
combination of phagocytosis by Kupffer cells and a accumulation of platelets 
in the sinusoids. Increased fibrinolytic activity is apparently caused by 
primary activation in the hepatic graft. 
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INTRODUCTION 
Orthotopic liver transplantation (OL T) is associated with serious bleeding 
problems, which often require the use of large amounts of blood products 
(1,2). Data from clinical studies suggest that bleeding of surgical origin may 
be enhanced by disturbances of the hemostatic system and blood loss seems 
to be at least to some extent dependent on intraoperative deteriorations of 
the hemostatic function (3,4). A dangerous period of hypocoaguloability has 
been recognised especially after reperfusion of the new liver ( 4,5), suggesting 
a direct effect of the reperfused donor liver on the hemostatic system. 
A decrease in platelet count is one of 
seen after recirculation of the donor liver, 
the changes that are uniformly 
despite the infusion of platelets 
sign of disseminated intravascular 
isolated phenomenon and several 
(3,6). Although thrombocytopenia may be a 
coagulation (DIC), it is often seen as an 
investigators 
the graft. 
have proposed other 
Hutchison et al (6) 
extravasation of platelets into the 
their publication no photographs 
Schalm et al. (7) suggested a 
mechanisms for platelet sequestration in 
reported morphological evidence for the 
spaces of Disse after canine OLT, but in 
of histopathologic preparations were shown. 
reversible platelet aggregation in association 
with an increased activity of the reticuloendothelial system after graft 
reperfusion, but in this study no objective evidence by histologic studies was 
given. The exact mechanism underlying thrombocytopenia after OLT is 
therefore still not clear. 
Another phenomenon that has been described after graft recirculation in 
OLT is an increase in fibrinolytic activity (4,8). It is still a matter of 
debate whether hyperfibrinolysis in OLT is a primary process or secondary 
to DIC. Some investigators observed increased fibrinolytic activity in 
combination with signs 
fibrinolysis (5,9). Others 
of DIC and suggested a secondary activation of 
could not find important signs of DIC (4,10) and 
direct histologic evidence for the presence of fibrin deposits in liver grafts 
after recirculation has never been found. Therefore, primary activation of 
the fibrinolytic system has been proposed as an important underlying 
mechanism of the hyperfibrinolysis after graft recirculation (10, 11). However, 
the mechanism and origin of this fibrinolytic activation are still unclear. 
In this study we investigated the role of graft reperfusion in the origin of 
thrombocytopenia, as well as coagulation and fibrinolytic disorders in 
orthotopic and auxiliary liver transplantation in pigs. In order to find 
morphologic evidence for microthrombi and/or platelet sequestration, electron 
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microscopy was performed on biopsies from the transplanted livers. Further-
more, hemostatic parameters in venous blood from the liver grafts were 
examined in comparison with peripheral blood samples of the general circula-
tion. 
MATERIALS AND METHODS 
In all experiments female Yorkshire pigs were used, weighing 23.5 ± 3.3 
kg (mean ± SD; n::::l8). Nine animals received an orthotopic transplant and 
heterotopic, auxiliary liver transplantation was performed in nine other pigs. 
The animals were used in a comparative study on the surgical techniques of 
orthotopic and heterotopic, auxiliary partial liver transplantation, the results 
of which will be described elsewhere. Details of the surgical procedures 
relevant to this study are given below. 
Donor hepatectomy was performed using a conventional technique. Livers 
were preserved by means of an ex-vivo cold perfusion (4°C) via the portal 
vein, with one liter Euro-Collins and used for transplantation within 4 hr. 
OLT was performed by a standard procedure (12). Heterotopic transplan-
tation of a partial, auxiliary liver graft (APLT) was performed after resec-
tion of the left medial and lateral lobes of the donor liver during bench 
surgery, as described previously (13). The partial liver was inserted in the 
right upper abdominal cavity, anastomosing the donor infrahepatic vena cava 
to the host suprahepatic vena cava and the donor portal vein end-to-side to 
the host portal vein. The donor hepatic artery was anastomosed end-to-side 
to the infrarenal aorta and the intrahepatic part of the donor vena cava was 
ligated. 
Ultrastructural and morphological studies 
Wedge-like liver biopsies of about 2 gram were taken 5-10 min after graft 
reperfusion in 9 consecutive transplantations (6 OLTs and 3 APLTs). Pieces 
of liver were fixed for transmission electron microscopy either by immersion 
fixation in ice cold 3% glutaraldehyde or by perfusion fixation. Liver tissue 
fixed by immersion fixation was further processed according to standard 
procedures. For the perfusion fixation the liver biopt was canulated by a 
Braunula 0.5-G 18 into a larger vessel exposed at the periphery of the tissue 
block and secured tightly and perfused with buffered saline for 2 min, 
followed by 2% glutaraldehyde in 0.15 M sodium cacodylate buffer pH 7,4 for 
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5-10 min. All solutions were used at 10 °C. Postrepertusion was done with 
0.05 M Tris - HCl buffer containing 7% sucrose for 6 min. The flow rate was 
about 5 ml/min. Vibratome sections of 150 f.tm were cut and postfixed in 1% 
Os04 in 0.15 M sodium cacodylate buffer for 45 min, dehydrated in a graded 
series of ethanol and embedded in LX 112 (Ladd Research Industries, Inc., 
Burlington, Vermont). Transmission electron microscopy was performed 
according to routine procedures (14). Ultrathin sections were contrasted with 
uranyl acetate and lead citrate, and examined in a Philips EM 410. 
Hemostasis studies in graft blood 
Collection of blood. 
In order to examine the direct effect of the donor liver on hemostasis, 
blood samples were taken from the first venous effluent from the graft 
after recirculation. After completion vein anastomosis, the 
graft was reperfused, 
tion was prevented 
clamped off. In OLT, 
while reentrance 
of the portal 
of blood into the systemic circula-
anastomosis temporarily 
vein 
taken 
(before 
from 
by leaving 
blood was 
suturing), using 
the infrahepatic 
a 20 
vena 
the vena cava 
taken from the donor infrahepatic caval 
ml plastic syringe. In APLT, blood was 
cava before it was ligated. After graft 
blood was obtained in this manner, the caval venous clamp was removed, 
allowing complete systemic recirculation. For reference values, systemic 
blood samples (20 ml each) were taken from an arterial line, during the 
first period of the recipient operation (systemic pre-perfusion sample) and 5 
min after recirculation of the donor liver (systemic post reperfusion sample). 
In OLT, systemic pre-perfusion samples were taken shortly before the end of 
the anhepatic period to avoid measuring effects already present during this 
period. 
Eighteen ml of each blood sample was immediately transferred to two 
polystyrene tubes, containing 1 ml ice cold trisodium citrate 0.11 mol/1 (9vol 
+ lvol) and immediately placed on melting ice. Another 2 ml was collected 
into 0.045 ml 15% sol 6.75 mg EDT A. Citrated blood was centrifuged (2800 g, 
4°C, 30 min) and plasma was collected, snap-frozen and stored in small 
aliquots at -70°C until used. 
Assays. 
Platelet count and mean platelet volume (MPV) were determined in EDTA-
treated blood, using a Platelet Analyser 810 (Baker Instruments, Allentown, 
PA, U.S.A.). The activated partial thromboplastin time (APTT), prothrombin 
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time (PT) and thrombin time (ThT), were employed as described previously 
(15). Fibrinogen was measured according to Clauss (16) and antithrombin-Ill 
(AT-III) activity was assayed according to Abildgaard et a! (17)_ Ctz-Anti-
plasmin (az-AP) activity and plasminogen were measured by chromogenic 
substrate methods (18,19). Euglobulin clot lysis time (ECLT) was determined 
as described previously (20), using standard euglobulin fractions of plasma, 
prepared at pH 5.9 with a plasma dilution of 1:10 (21). Hematocrit (Ht) was 
determined in EDT A-blood. 
Statistical Analysis. 
Statistical analysis was performed using the Wilcoxon signed rank test for 
paired data and the two-sample test for unpaired data. Values for p<0.05 
were considered to be significant. 
RESULTS 
Morphological studies 
Ultrastructural studies were performed on liver biopsies and in none of 
these biopsies signs of intravascular fibrin formation or platelet aggregation 
were found in the small sinusoids or larger vessels. In specimens fixed by 
perfusion fixation, both the sinusoidal cells and parenchymal cells showed a 
well-preserved ultrastructural morphology without signs of ischemic cell 
damage (figure 1). Especially the endothelial lining of the sinusoids was well-
preserved. Most platelets were found to lie free in the sinusoids, independent 
of the fixation technique. They showed cell processes and many of them 
seemed to have lost part of their granulae. Also ballooned platelets, lacking 
microtubules and granulae were seen (figure 2). In some cases phagocytosis 
of whole platelets by Kupffer cells was found (figure 3). Platelets were 
sometimes found extravascularly in the interstitial fibrous septa, but never in 
the space of Disse (figure 4). There were no differences found between 
livers transplanted in the orthotopic position and livers transplanted as 
auxiliary, heterotopic grafts. 
Fig. 1. 
Fig. 2. 
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Low magnification transmission electron micrograph with overview 
of hepatic cords and sinusoids. Some red blood cells (rbc) and 
numerous platelets are seen in the 
cells (ec), fat storing cells (fsc), and 
seen. Enlargement: 2,730 x. 
Platelets in a sinusoid forming some 
of their secretory granulae (arrow) 
15,840 X. 
sinusoids (arrows). Endothelial 
Kupffer cells (kc) can also be 
cell processes. They lack most 
and microtubules. Enlargement: 
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Fig. 3. Kupffer cells with internalized platelets (arrows). Enlargement: 
10,340 x. 
Fig. 4. Low power magnification of parenchym cells, sinusoid (sin), blood 
vessel (blv), space of Disse (d) and a bileduct (bd). Most of the 
platelets can be seen in sinusoids and blood vessels, but one is 
present in the fibrous septa (arrow). Also a polymorph nucleocyte 
(pmn), a mast cell (me), and fibroblasts (fb), are illustrated. 
Enlargement: 2,130 x. 
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Hemostasis studies in graft blood 
Comparison of platelet count and mean platelet volume in systemic pre-
repetfusion samples, graft samples and systemic post-reperfusion samples is 
shown in figure 5. A significant drop in platelet count was found in systemic 
post-reperfusion blood, when compared with the preperfusion values (p<O.Ol). 
This systemic effect was not different in OLT and APLT and there was no 
difference in platelet number in graft blood of the two groups. There were 
no indications that the observed platelet gradient across the graft was due 
to a reduction of platelets of a specific size, since no differences were 
found in MPV of the three samples in both groups. 
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Fig. 5. Direct effect of reperfusion of orthotopic (OLT) and auxiliary 
(APLT) liver grafts on platelet count and mean platelet volume 
(MPV). PRE, systemic pre-perfusion sample; GRAFT, graft blood and 
POST, systemic post-reperfusion sample. 
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The results of the coagulation parameters and Ht values are shown in 
table lA. In general, no serious changes in the coagulation system were 
found after graft reperfusion. None of the investigated coagulation para-
meters in graft blood was significantly different from the systemic reper-
fusion values. There were also no significant differences in hematocrit 
values of the three blood samples in both types of transplantation. 
Table lA. 
APIT 
(sec) 
PIT 
(sec) 
ThT 
(sec) 
Fibrinogen 
(g/1) 
AT-III 
(%) 
Ht 
Comparison of coagulation parameters and hematocrit before 
and after reperfusion of orthotopic (OLT) and auxiliary partial 
(APLT) liver transplants (n=9 in both groups) 
OLT 
APLT 
OLT 
APLT 
OLT 
APLT 
OLT 
APLT 
OLT 
APLT 
PRE 
median 
(range) 
19 (15-24) 
16 (15-20) 
14 (12-18) 
14(11-16) 
37 (27-60) 
47 (37-60) 
0.9 (0.5-1.6) 
1.8 (1.3-2.1) 
70 (43-102) 
120 (77-154) 
OLT 0.26 (0.22-0.33) 
APLT 0.30 (0.25-0.38) 
GRAFT 
median 
(range) 
24 (19-35) 
32 (15-37) 
17 (14-20) 
20 (12-25) 
42 (32-55) 
35 (17-53) 
0.7 (0-1.1) 
1.1 (0-1.4) 
55 (35-58) 
45 (22-78) 
0.28 (0.20-0.43) 
0.35 (0.20-0.45) 
POST 
median 
(range) 
21 (17-28) 
20 (16-26) 
15 (12-20) 
15 (13-24) 
41 (29-60) 
35 (16-46) 
0.7 (0-1.5) 
1.2 (0.6-1.4) 
50 (47-74) 
56 (42-95) 
0.27 (0.21-0.30) 
0.29 (0.24-0.35) 
The abbreviations used are: PRE, systemic pre-perfusion; GRAFT, graft 
blood; POST, systemic post-reperfusion. 
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The effect of graft reperfusion on fibrinolysis is shown in table lB. 
Fibrinolytic activity, as measured by the ECLT, was increased in systemic 
blood after reperfusion, compared with the pre-perfusion values m both 
OLT and APL T (p<0.05). Shortest ECLTs were found in the graft blood 
samples of both orthotopic and auxiliary grafts (table lB). In the APLT 
group, values of ECLT in graft blood were shorter than the systemic post-
reperfusion values (p<0.05). Changes in a2-antiplasmin and plasminogen were 
less prominent (table lB). Only in the APLT group a reduction of a 2-
antiplasmin was found in graft blood, when compared with the systemic 
post-reperfusion values (p<0.05). 
Table lB. 
ECLT 
(min) 
a%-AP 
( 0) 
Plasminogen 
(%) 
Comparison of fibrinolytic parameters before and after reper-
fusion of orthotopic (OLT) and auxilary partial (APLT) liver 
transplants (n=9 in both groups) 
PRE GRAFT POST 
median median median 
(range) (range) (range) 
OLT 180 (55-180) 75 (45-180)* 115 (60-180) 
APLT 180 (180-180) 40 (15-180)* 120 (25-180) 
OLT 43 (24-72) 33 (22-65) 35 (22-61) 
APLT 88 (63-109) 25 (19-74)** 43 (10-67) 
OLT 50 (25-65) 38 (21-50) 43 (10-67) 
APLT 94 (66-104) 29 (10-55) 37 (24-54) 
ECLT, euglobulin clot lysis time; a 2-AP, o:2-antiplasmin; other abbreviations 
as in table I A. *p<0.01, **p<0.05, compaired with the corresponding POST-
value. 
DISCUSSION 
Orthotopic 
platelet count, 
role in the 
caused by 
reactions or 
(6,22). Since 
74 
liver transplantation is often associated with a drop in 
which may lead to severe thrombocytopenia and may play a 
origin of hemorrhages (3,6). This thrombocytopenia may be 
an increased platelet consumption, hemodilution, immunologic 
by a sequestration of platelets in the reperfused liver graft 
signs of DIC, characterized by a simultaneous decrease of 
coagulation factors and presence of fibrin degradation products are not 
invariable found in liver transplantation, the role of platelet sequestration in 
the liver graft has been subject of speculations and further research. 
In the present study we observed a significant drop in platelet count in 
the systemic circulation after reperfusion of auxiliary and orthotopic liver 
grafts. Fall in platelet count was unlikely to be caused by hemodilution since 
no significant differences were found in hematocrit values of the correspon-
ding blood samples. Recently, a specific accumulation of platelets in the 
newly grafted liver was suggested by platelet labeling studies (22). In this 
study we provided additional evidence that the systemic decrease of platelet 
count is due to a process of platelet accumulation in the liver graft, since a 
sharp drop of platelet count was found in the venous outflow of the graft 
after reperfusion. 
Only a few histopathological studies have been performed in the first 
hours after transplantation, in order to find morfological evidence for the 
mechanism of platelet accumulation in the reperfused liver graft (6,8). Groth 
et al. (8) and Hutchison (6) performed electron microscopy studies after 
canine and human OL T and described an extravasation of single, undamaged 
Disse. By performing electron platelets into 
on 
the perisinusoidal space 
biopsies taken 5-10 min 
of 
after graft recirculation microscopy 
found some evidence for the extravasation of platelets into the 
we indeed 
interstitial 
fibrous septa. But the number of platelets found extravascularly was neglec-
table in comparison with the number in the sinusoids. The difference 
between the earlier studies and our observations may be due to differences 
in period of time after revascularisation. We found a rather well-preserved 
endothelial lining of the sinusoids and no widening of the space of Disse. In 
conformity with other studies (6,8,23) we could not find morphologic 
evidence of microthrombi or platelet aggregates in the sinusoids. The problem 
remains as to what happens with the blood platelets during reperfusion of 
the liver graft. In some preparations we observed phagocytosis of whole 
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platelets, normal in appearance, by Kupffer cells. Comparable observations 
have been made by other investigators (6,24). Cassel (24) observed phago-
cytosis of whole platelets by Kupffer cells at a much later stage (138 days) 
after OLT in pigs. He proposed an increased reaction of Kupffer cells of the 
transplant against host thrombocytes as a possible mechanism for thrombo-
cytopenia after liver transplantation (24). Our data suggest that this process 
may also contribute to the drop of platelets early after graft reperfusion. 
Interesting was the agranular appearance of the platelets that were lying 
free in the sinusoids. This might be a sign of slight platelet activation, 
which was just not strong enough to cause complete platelet aggregation 
(25). Release of granulae may not be a result of mechanical stress activation, 
as should occur during perfusion fixation, seen the differences in ultrastruc-
tural characteristics of platelets which 
blood platelets become non-functional 
are mechanically activated (26). Since 
after loosing their granulae (25), the 
finding of agranulair platelets may be compatible with the acquired platelet 
dysfunction and the process of delayed release of non-functionating platelets 
into the circulation after liver graft perfusion, as suggested by Schalm et al. 
(7). It is well known that large platelets have a higher potential of throm-
boxane A2 and are more prone to activation than smaller platelets (27). We 
did, however, not find any difference in mean platelet volume (MPV) before 
and after graft reperfusion, indicating that there seems to be no preferential 
sequestration of larger, and hence more reactive platelets during liver graft 
reperfusion. 
Analysis 
lation did 
of the blood samples of the first hepatic outflow after recircu-
not reveal any serious changes of the investigated coagulation 
parameters, when compared with the systemic values. These observations are 
in agreement with the results of recent large clinical studies (3,4) and 
suggest that reperfusion of optimal and short-term preserved livers has no 
important acute effect on the coagulation system. Lack of signs of clinical 
relevant activation of the clotting system confirms that the observed 
decrease of platelet count is unlikely to be due to a process of DIC. 
On the other hand, we observed a significant increase of fibrinolytic 
activity, as measured by the ECLT, in the blood samples of the hepatic 
outflow of both orthotopic and auxiliary grafts. We could not find convin-
cing evidence for DIC by either histopathologic or hemostasis studies, 
therefore we think that the increased fibrinolytic activity is of primary 
origin. Since the ECLT measures predominantly tissue-type plasminogen 
activator (t-PA), it is likely that an increase of t-PA levels in the circu-
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lation has caused the observed increase in fibrinolytic activity. The more so 
as it was recently demonstrated that systemic hyperfibrinolysis in human 
orthotopic (28) and auxiliary partial liver transplantation (29) is related with 
increased plasma levels of t-PA. The mechanisms underlying the increased 
release are still unclear and need further study. 
In conclusion, the most prominent early effects of graft reperfusion on 
hemostasis, found in this study, were a drop of the platelet count and 
increase in fibrinolytic activity. By using electron microscopy we could not 
find any evidence for intravascular coagulation or platelet aggragation. Early 
changes in platelets may be partly due to phagocytosis by Kupffer cells. 
Increased fibrinolytic activity appeared to be a primary process, originating 
from the reperfused liver graft. 
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SUMMARY 
In spite of its unpredictable kinetics, heparin is still not generally 
monitored during peripheral vascular surgery. To evaluate heparin levels and 
neutralisation, plasma heparin concentrations were measured using a chromo-
genic substrate method during 20 consecutive operations on the Abdominal 
Aorta. This was combined with measuring activated partial thromboplastin 
time (APTT), thrombin time (ThT), prothrombin time (PT), antithrombin-III 
(AT-III) and fibrinogen concentration. Heparin concentration 5 min after 
administration and the elimination rate showed a wide variation. Using a 
standard dosage for all patients resulted in plasma levels that are potentially 
too low in some patients. The APTT and ThT were found to be unsuitable 
for an exact calculation of heparin levels. Protamine administration based on 
the surgeon's judgement of hemostasis was inadequate. Furthermore an intra-
operative decrease of AT-III and fibrinogen was seen in eight patients. It is 
advisable and possible to have direct monitoring of heparin concentration 
during peripheral vascular surgery. 
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INTRODUCTION 
Surgery on bloodvessels without frequent thrombotic complications has 
become possible by the use of intraoperative anticoagulation. Since the first 
described use of heparin as an anticoagulant in vascular surgery in 1940 (I), 
a variety of regimens have been described. Most vascular surgeons use a 
standard dose with an average of 5,000 to 8,000 units given intravenously 
(2,3), usually without monitoring its anticoagulant effect. Others use a 
bodyweight dependent dose of heparin i.v. (4-6). Recently we have become 
more aware of the complex and individually variable kinetics of heparin, 
which makes it impossible to predict the activity and elimination of heparin 
in an individual person after a standard dose is given intravenously (7-10). 
Although monitoring of heparin activity during cardiopulmonary bypass is 
a standard procedure and some authors have emphasized the need for a 
close monitoring during peripheral vascular surgery also, its measurement 
during this type of surgery is only slowly gaining acceptance (11-15). The 
most widely used tests for monitoring heparin are the whole-blood clotting 
time (16-18) and the activated partial thromboplastin time (19). However, 
with these tests, heparin activity is measured only indirectly and recent 
evidence indicates that these methods correlate poorly with heparin levels 
(13,20). 
With a more recently developed test, 
substrate for factor Xa, heparin activity can 
using a specific chromogenic 
be measured directly (21). This 
offers a method of more precise monitoring of heparin activity and an exact 
calculation of the protamine dose necessary for heparin neutralisation. As far 
as we know this has not been evaluated in vascular surgery before. To use 
this method in combination with standard clotting assays in one apparatus, 
one should be able to perform both kinetic assays (chromogenic substrates) 
and end-point assays (clotting assays). We used a spectrophotometer in which 
both methods can be rapidly performed. Its compactness made it possible to 
use it easily in the operating theatre. 
This communication reports the use of a chromogenic substrate method 
for monitoring heparin in combination with clotting assays during 20 
abdominal aortic reconstruction procedures. 
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PATIENTS AND METHODS 
Patients 
The hemostasis parameters and heparin concentration were monitored 
during 20 consecutive, elective abdominal aortic bifurcation prosthesis 
operations. The ages of the patients ranged from 39 to 72 years, with a 
mean of 57.8 years. The weight ranged from 56 to 84 kg, a mean of 68.7 kg. 
Standard operative techniques were used in all procedures. Dextran 40 
(RheomacrodexR, Pharmacia Fine Chemicals, Uppsala, Sweden) was used to 
substitute plasma volume, at a dose of 10 ml/kg body weight (10% (w/v) 
dextran in 0.9% NaCl). A standard dose of ±5,000 IU heparin (Thrombo-
liquineR, Organon, Oss, The Netherlands) was given by intravenous injection, 
about 10 min prior to clamping of the vessels. After completion of the 
anastomosis and removal of the clamps, protamine was administered, the 
amount varied between zero and 50 mg, depending on the time passed after 
heparin administration and the judgement of the surgeon. 
Material 
A FP-9 10 coagulation system (Lab systems, Helsinki, Finland) is a combina-
tion of a spectrophotometer, an analyzer. an incubator with thermoblocks, a 
mixer and 9-channel pipettes. The instrument is designed for conventional 
clotting assays, chromogenic methods and enzyme immunoassays with micro 
or semi-micro reagent volumes. Nine samples can be measured in one 
cuvetteblock by means of the vertical measurement principle., range 340-620 
nm. For this study the FP coagulation system and an Eppendorf centrifuge 
were placed in the operating theatre. 
Thrombin and ActinR (activated cephaloplastin reagent) were obtained 
from Merz Dade, Dijdingen, Switzerland; SimplastinR from General Diag-
nostics, Morris Plane, New Jersey, U.S.A. Acetate-Veronal buffer was 
prepared according to Michaelis, pH7 .4. Thrombin was dissolved in Michaelis 
buffer with final concentrations of ±3 IU/ml. 
Normal plasma, necessary for the heparin assay and used as control 
sample for other assays was obtained from twenty apparently healthy 
hospital staff volunteers (male/female ration about l). Plasma was pooled 
and stored in I ml aliquots at -70°C. 
Methods 
Blood was collected from an arterial line into 3.2% trisodiumcitrate 
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(9v/l v). The first 10 ml of blood were discarded to remove traces of 
heparin from the line. All samples were centrifuged immediately in an 
Eppendorf centrifuge (3.5 min, 10,000 g, R.T.). After separation, plasma 
samples were kept on melting ice (0°C) until measured. Activated partial 
thromboplastin time (APTT) was determined with ActinR (22) (N: 22-37 s). 
Prothrombin time (PT) was assayed according to Quick (23), with Simplas-
tinR (N: 10-14 s). Thrombin time (ThT) was measured by adding 200 ).11 
Thrombin (±3nJ/ml) to 200 ).11 prewarmed plasma (24) (N: 10-15 s). Fibri-
nogen was assayed according to Clauss (25) (N: 1.2-4.8 gil). Antithrombin-
III (AT-III) activity was measured using an amidolytic method (26) with the 
synthetic peptide substrate S-2238 (CoatestR antithrombin, Kabi Vitrum 
Haematology bv., Amsterdam, The Netherlands) and expressed in U/ml 
(normal plasma 1.00 U/ml). Heparin concentration was determined by 
measuring anti-factor Xa activity, using the chromogenic substrate S-2222, 
bovine factor Xa and human AT-III concentrate (21) (CoatestR heparin, Kabi 
Vitrum Haematology BY, Amsterdam, The Netherlands). Blood samples were 
taken after induction of anaesthesia, 5 min after heparinisation, and subse-
quently every 30 min until heparin neutralisation with protamine chloride and 
5 min afterwards. 
RESULTS 
Hemostasis parameters 
In all plasma samples the APTT, PT, ThT, fibrinogen and antithrombin-
III concentrations were determined. There were no major abnormalities of 
the investigated parameters in the samples taken prior to heparin administra-
tion, except for an unexplained prolongation of the APTT in one case (50s). 
Five minutes after heparin administration, APTT and ThT were longer 
than 180 s and 60 s, respectively (upper limits of measuring time), which 
indicated that a good heparin effect was obtained in all but one case, 
which will be discussed in the section on Case Reports. However the exact 
heparin concentration could not be measured with these assays. 
AT-III and fibrinogen concentrations did not remain constant during the 
operation in all cases. A decrease of AT-III of more than 25% of the initial 
value was seen in 10 patients, which resulted in values lower than 0.50 U/ml 
in 8 of these patients. AT-III decrease was combined with a decline in 
fibrinogen of more than 25% of the initial value in 6 cases. 
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Heparin monitoring 
The standard dose of heparin, when divided by the patient's weight, 
resulted m median dose of 68.5 IU/kg (range 40.0 to 86.2 IU/kg). The 
median heparin concentration measured 5 min after heparinisation was 0.9 
IU/ml (range (0.2 to 2.8 IU/ml). The elimination of heparin from plasma for 
all cases is shown in Figure 1. The period between heparin administration 
and neutralisation by protamine varied between 47 and 132 min (median 95 
min, n=15). Based on the individual surgeon's judgement of hemostasis no 
protamine was given in 5 cases. Heparin activity was still measurable at the 
end of the operation in four of these patients (range: 0.2-0.8 IU/ml) and the 
heparin level in only one case was below the detection limit of the assay 
(<0.05 IU/ml). The dose of protamine chloride, administered in the other 15 
patients, varied between 20 and 40 mg, primarily based on empirical data and 
preference of the surgeon. No heparin was detectable after protamine 
administration in any of these cases. 
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Case Reports 
In Figure 2 data on three operations with unusual patterns of hemostasis 
parameters (cases B-D) are compared with a representative case with a 
normal course (case A). 
Case A: This patient represented a normal course (Fig.2). The heparin 
concentration 5 min after administration was 0.9 IU/ml. During the operation 
the heparin level fell gradually to 0.4 IU/ml at the end, just before prota-
mine was given. As can be seen from Figure 2, the APTT remained prolonged 
while heparin concentrations already decreased. This was also found for the 
thrombin time (data not shown). Both AT-III and fibrinogen levels remained 
stable at normal values during the operation. 
Case B: This operation was complicated by the formation of thrombi. The 
initial plasma heparin concentration 5 min after a bolus injection of 4,000 IU 
heparin i.v. (57.1 IU/kg) was low (0.6 IU/ml) (Fig.2). Together with a fast 
disappearance of heparin, this resulted in a shorter period of optimal 
heparinisation (±45 min) than expected from the initial dosage. This may 
have contributed to the formation of thrombi, that were seen in both the 
left and right iliacal artery at the end of the procedure. A thrombectomy 
was performed successfully, showing two freshly formed thrombi on a pre-
existing artheromatous degenerated vessel wall. At that moment the heparin 
concentration was 0.1 IU/ml and APTT was 45 s. Based on the clinical 
findings the surgeon decided to give an extra dose of 2,000 ru heparin after 
which the heparin level rose to 0.5 IU/ml and APTT was longer than 180 s. 
Case C: A patient with low levels of both AT-III and fibrinogen. A 
remarkable decline of both AT -III and fibrinogen concentrations to 30% and 
37% of the initial value respectively, was seen in this case, which finally 
resulted in values of 0.35 U.ml and 0.8 gil respectively (Fig.2). 
Case D: During surgery AT-III levels decreased and reached values below 
the sensitivity of the assay (0.05 U/ml) at the end of the operation (Fig.2). 
Fibrinogen levels, however, remained in the normal range. 
Logistic data on the coagulation system 
Using the FP-910 coagulation system anti-factor Xa heparin activity 
could be measured within 10 min after a blood sample was taken. The 
complete program, by which APTT, PT, ThT, fibrinogen, AT-III and heparin 
concentration were assayed could be performed within 30 min after blood-
sampling. The intra- and intervariations of the assays are shown in Table 1. 
These data are comparable to other systems (e.g. coagulometer) and reflect 
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the applicability of this system. The costs for the total program of assays, 
measured per sample, together with control samples are approximately $15.00 
for chemicals and $1.50 for disposable materials. 
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Fig. 2. Coagulation data of one patient as a representative example of a 
stable coagulation profile during surgery and three complicated 
cases. Case A: Normal pattern of hemostasis parameters and gradual 
disappearance of heparin; Case B: An extra dose of 2,000 IU 
heparin was necessary after a thrombotic complication during a 
period of low heparin concentration; Case C: Intraoperative decline 
of both AT-III and fibrinogen; Case D: Extreme intraoperative 
decline of AT-Ill. 
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Table l. Intra- and inter-assay variations on the FP-910 coagulation 
analyser 
Intra-assay Inter-assay 
variations variations 
Heparin 4.9% 8.9% n~36 
APTT 1.8% 5.0% n~5 
Thrombin time 3.9% 3.8% n~5 
Prothrombin time 3.3% 4.6% n~41 
Fibrinogen 7.5% 11.0% n~36 
Antithrombin Ill 5.0% 6.1% n~36 
DISCUSSION 
Since the first described use of heparin as an anticoagulant in vascular 
surgery by Murray in 1940 (1), heparinisation has become standard procedure 
during this type of surgery (2). 
Most surgeons use standard regimens for heparin administration without 
monitoring its activity. In recent years knowledge of the kinetics of heparin 
has considerably increased and we now know that heparin response after a 
single dose is unpredictable and the elimination rate has a wide individual 
variation, making it impossible to predict individual heparin effect, even 
when a body weight dependent dosage is used (7 -9). In the few studies on 
monitoring of heparin in vascular surgery, usually indirect clotting assays, 
e.g. the activated clotting time, were used (3,11,12). However, these assays 
have been demonstrated to correlate poorly with heparin levels (13,20). 
We report here for the first time the measurement of heparin concen-
tration during vascular surgery with a direct chromogenic substrate method. 
This chromogenic substrate assay and the clotting assays used in this study 
were shown to have an acceptable 
reflects a good reproducibility and 
intra- and inter-assay variation, which 
reliability, whether performed in the 
laboratory or the operating theatre. We demonstrated that, with the chromo-
genic substrate assay, heparin concentration could be measured within 10 min 
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after blood sampling thus allowing it to be measured at regular intervals. By 
doing so it is, theoretically, possible to prevent over- or underheparinisation 
and to calculate the exact protamine dose. 
What relevant outcomes were obtained from this study? 
Firstly, by using the chromogenic substrate method we showed a wide 
variation in heparin response and elimination after a single intravenous 
dose, compatible with other studies in vascular surgery using different 
methods (3,11,15). These differences in elimination rate resulted in low 
heparin levels, faster than expected in some cases. However, in the literature 
there is no consensus on the minimal heparin concentration necessary to 
prevent thrombotic complications during vascular surgery. Based on studies of 
the prevention and progression of a thrombotic process in non-surgical 
patients a range of 0.2-0.5 IU/ml heparin was found to be effective (24,27). 
During surgery, however, the operative trauma may lead to activation of the 
clotting system, which probably requires higher heparin concentrations to 
prevent fibrin formation. This is also found during hemodialysis, for which it 
has been demonstrated that full suppression of fibrinopeptide A generation 
requires heparin anti-Xa levels of 0.7-LO IU/ml (28). It is likely that the 
same heparin concentration is needed during major vascular surgery, while 
the much higher levels (above 2.0 IU/ml) used during cardiopulmonary bypass 
may not be necessary (29,30). As can be seen in Figure I we found heparin 
levels to fall below the assumed effective level of 0.7-1.0 IU/ml in most 
cases. On the other hand, the complex kinetics of heparin were once more 
illustrated by the fact that, based on the time past after heparin administra-
tion and the surgeon's judgement in 4 patients no protamine was given, 
while in fact heparin was still measurable. 
Secondly, the activated partial thromboplastin time (APIT) and the 
thrombin time (ThT) were found to become excessively prolonged at higher 
heparin levels. When heparin concentrations decreased, as measured with the 
chromogenic substrate assay, the APTT and ThT often remained longer than 
the fixed measuring time (180 s and 60 s, respectively). This demonstrates 
the insensitivity of these 
determination of heparin 
surgery. 
assays, which makes them unsuitable for an exact 
concentration at the levels used during vascular 
Thirdly, this study showed a change in antithrombin-III and fibrinogen 
concentrations rn patients undergoing major vascular surgery. Since the 
anticoagulant effect of heparin is known to be a result of its accelerating 
effect on inhibition of thrombin and factor Xa (and to a lesser degree factor 
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!Xa and Xla) by AT-III (31,32), a decrease of AT-Ill to values lower than 
0.50 IU/ml, as seen in 8 of the 20 patients may be of clinical importance. 
Although different explanations have been proposed to explain a decrease of 
AT-III during heparinisation or surgery (30.33-38), the cause of the decrease 
of AT -III, found in this study is still unclear. 
In conclusion we can state that the individual differences in heparin 
kinetics, together with the changes in hemostatic parameters, found in 
patients undergoing major vascular surgery, warrants close monitoring in 
each patient. We have demonstrated that for this purpose the chromogenic 
substrate assay for heparin is feasible and it can be quickly performed in 
the operating theatre in combination with different hemostatic parameters. 
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SUMMARY 
Orthotopic liver transplantation is frequently associated with hyper-
fibrinolysis. The origin and clinical relevance of which are largely unknown. 
In 20 orthotopic liver transplantations we studied the occurrence and 
systemic effects of hyperfibrinol ysis. Severe fibrinolysis was defined to be 
present when the euglobulin clot lysis time and the whole blood clot lysis 
time, as measured by thrombelastography, were shorter than 60 and 90 min 
respectively, at some time during the operation. Based on these criteria, 
seven patients had minimal fibrinolysis (group I), and thirteen patients had 
severe fibrinolysis (group II). In group II a gradual increase of t-PA activity 
was seen during the anhepatic stage, followed by an "explosive" increase 
immediately after graft reperfusion (P=0.0004, compared with group I), and a 
reduction of PAl activity. Plasma degradation products of fibrinogen and 
fibrin increased parallel to t-PA activity and levels were significantly higher 
at 45 min after graft reperfusion in group II compared with group I (p<0.04 ). 
Thrombin-antithrombin III complexes showed an identical steady increase in 
both groups, indicating that increased t-PA activity was not related to 
thrombin formation. A combination of increased endothelial release and 
reduced hepatic clearance may have caused the increased t-PA activity. The 
t-PA associated destruction of fibrinogen and fibrin after graft reperfusion is 
consistent with the clinical signs of severe oozing often seen in this period. 
These observations may have important clinical implications for the treatment 
of bleeding in patients undergoing orthotopic liver transplantation. 
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INTRODUCTION 
Orthotopic liver transplantation has become an accepted and clinically 
useful treatment for patients with a variety of irreversible liver diseases (1 ). 
The gradual improvements of the surgical technique, anesthesiologic manage-
ment and immunosuppressive therapy have contributed to an increase in the 
success rate and long-term survival (1 ,2). The surgical operation, however, is 
an extensive procedure, which may be frequently associated with serious 
bleeding, requiring massive blood transfusions (3). Maintenance of surgical 
hemostasis may be seriously complicated by disturbances in the hemostatic 
system. Previous studies have suggested an important role of hyperfibrino-
lysis in the origin of bleeding complications during orthotopic liver trans-
plantation (4,5) 
Recently, studies involving only a few subjects have shown that the 
hyperfibrinolysis during orthotopic liver transplantation may be related to 
increased plasma levels of tissue-type plasminogen activator (t-PA) (6,7), a 
key enzyme of the fibrinolytic system (8). Under normal physiological 
conditions t-PA activity in the circulation is low, due to its rapid inacti-
vation by formation of complexes with FA-inhibitors (PAl), but t-PA activity 
may increase several fold after specific stimuli (8). Both t-PA and its major 
inhibitor (PAI-l) are produced and secreted by endothelial cells, whereas 
hepatocytes and blood platelets are additional sources of PAI-l (8,9). 
Elimination of t-PA from the blood is mainly regulated by the liver with a 
tl/2 of 3-5 minutes (10). Increased levels of t-PA during orthotopic liver 
transplantation probably result from a combination of increased endothelial 
release and decreased hepatic clearance during the anhepatic stage (6). The 
mechanisms underlying the increased release of t-PA and the role of PAl in 
the regulation of t-PA activity during liver transplantation, however, are 
still unknown. 
Some investigators have suggested that hyperfibrinolysis in orthotopic 
liver transplantation may be secondary to disseminated intravascular coagu-
lation (DIC) (7,11,12). Differentiation between secondary and primary 
fibrinolytic activity, however, has been difficult, mainly due to lack of 
appropriate laboratory tests. Lack of specific parameters has also hampered 
the assessment of the role of increased fibrinolytic activity in the actual 
breakdown of coagulation factors and the development of a bleeding diathe-
sis. Especially under strongly hyperfibrinolytic conditions fibrinogenolysis 
may also occur (13). Although increased serum levels of fibrin(ogen) degrada-
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tion products have been found during liver transplantation (4,11), whether 
these were the result of fibrin breakdown or plasmin destruction of fibrino-
gen could not be determined. 
and clinical relevance of In the present study we examined the origin 
hyperfibrinolysis in orthotopic liver transplantation. 
and PAl activity in combination with the separate 
degradation products of fibrinogen and fibrin enabled 
Measurement 
quantitation 
us to study 
of t-PA 
of plasma 
the origin 
of hyperfibrinolysis and its role in the development of a systemic lytic state. 
Thrombin-antithrombin Ill (TAT) complexes were measured to study the role 
of clotting activation and thrombin formation in the origin of hyperfibrino-
lysis. 
MATERIALS AND METHODS 
Patients 
Twenty three adult patients who underwent their first liver transplan-
tation at Presbyterian University Hospital between June 1st and 27th, 1988 
were observed prospectively. In an otherwise consecutive series, three 
patients of whom more than two blood samples were missing due to technical 
errors, were omitted. The remaining 20 patients were categorized by patho-
logical diagnosis as described previously (14). Five different diagnostic 
groups could be distinguished, as shown in table I. 
Table 1. Diagnosis and characteristics in 20 patients undergoing ortho-
thopic liver transplantation 
Diagnosis No. F M Age range 
Postnecrotic cirrhosis 9 3 6 27- 54 
Primary biliary cirrhosis 5 5 27-60 
Sclerosing cholangitis 3 2 29- 41 
Carcinoma 63 
Miscellaneous * 2 22, 37 
Total 20 10 10 22-63 
*Two patients with Wilson's disease. 
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Orthotopic liver transplantation was petformed by a standard technique, 
using a vena-venous bypass in all patients (15). The surgical procedure can 
be divided into three stages. During the preanhepatic stage (stage I) the host 
liver is isolated. The anhepatic stage (stage II) begins with the clamping of 
the vessels of the native liver and ends with the completion of the vascular 
anastomosis of the graft liver. The postanhepatic stage (stage IIJ) lasts from 
graft reperfusion to the end of surgery. Intraoperative blood loss was 
compensated by the transfusion of modified whole blood (from which 
platelets have been removed) or packed RBC and fresh frozen plasma in an 
approximate ration of 1:1. In case of massive blood loss a rapid infusion 
system was used, by which a mixture of packed RBC, fresh frozen plasma 
and Plasmalyte A was infused in a ratio of 1 U: lU: 250 rnl. Platelets and 
cryoprecipitate were usually not given before stage III. All patients gave 
their informed consent for blood sampling during the operation, as part of 
the intraoperative patient care. 
Intraoperative blood samples for hemostasis monitoring were collected 
from an arterial line. Blood (9 ml) was collected in l ml 0.13 mol/! trisodium 
citrate and immediately centrifuged at 2800 g for 10 min. Plasma was either 
directly used for testing or frozen at -70 °C. Whole blood (0.36 ml) was used 
for thrombelastographic monitoring within 2 min after sampling. Blood 
samples were taken according to the following schedule: immediately after 
induction of anesthesia (BASE); 30 min before removing the liver (11-30); 5 
min in the anhepatic stage (11+5); 5 min before graft reperfusion (III-5); 5 
min after graft reperfusion (III+5); 45 min after reperfusion (III+45); 150 min 
after reperfusion (III+ 150) and at the end of the operation (END). 
Assays 
Standard hemostasis tests were performed using previously described 
methods (16,17). Thrombelastographic monitoring of whole blood coagulation 
and fibrinolysis was performed using a Thromb Elastograph-D (Haemoscope 
Corporation, Morton Grove, Ill). The whole blood clot lysis time (WBLT) was 
defined as the time between the maximum amplitude and the registration of 
complete lysis on the thrombelastographic recording (normal >150 min) (18). 
Levels of t-PA activity (normal range, 0-l IU/ml) and PAl activity were 
measured using chromogenic substrate methods (Coasets tPA and PAl, Kabi 
Vitrum Hematology, Stockholm, Sweden). For the measurement of t-PA 
activity 100 ul of plasma was acidified (pH 4.0 - 4.1) with 100 ul of acetate 
buffer and 20 ul of 20% acetic acid, both supplied in the assay kit. T-PA 
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activity was determined by measuring the amidolytic activity of plasmin onto 
the chromogenic substrate S-2251, after incubation in the presence of 
plasminogen and human fibrin(ogen) fragments (19,20). The fibrinolytic 
activity of t-PA was expressed in International Units (IU) assessed by 
calibration against the international standard of t-PA 
cells (lot 83/517, National Institute for Biological 
London, UK). PAl activity was measured by adding 
from human melanoma 
Standards and Control, 
40 IU/ml t-PA to an 
equal volume of plasma. After incubation for 10 min at room temperature 
samples were diluted with sterile water (1:80) and residual t-PA activity was 
determined as described above. PAl activity was expressed in arbitrary units 
(AU), defined as the amount which inhibits one IU of t-PA in 10 min (21) 
(normal, 0-40 AU/ml). 
Two different sandwich-type enzyme linked imrnunosorbant assays (ELISA) 
(Fibrinostika, Organon Teknika, Turnhout, Belgium) were used for the 
quantitation of plasma levels of fibrinogen degradation products (FgDP; 
normal <0.5 ~g/ml) and fibrin degradation products (FbDP; normal <0.5 
~g/ml). In both ELISAs a monoclonal antibody, which reacts exclusively with 
FgDP and FbDP and not with intact fibrinogen or fibrin, is used as catching 
antibody. The FgDP ELISA contains a monoclonal tagging antibody which is 
specific for covalently bound fibrinopeptide A. Since fibrinopeptide A is split 
off during the activation of fibrinogen by thrombin, this ELISA tags only 
FgDPs which result from the plasmin-mediated destruction of fibrinogen (22). 
The FbDP ELISA gets its specificity for FbDP by using a monoclonal 
antibody which is elicited with D-dimer as immunogen (23). 
TAT complexes (normal range, 1.0-4.1 ~g/1) were measured by an ELISA 
(Behringwerke, Marburg, FRG), based on rabbit antibodies to human thrombin 
and antithrombin III respectively (24). Samples with TAT levels exceeding 
the highest standard contained in the assay kit (60 ~g/1), were diluted (1:2 
or 1:4) in normal pooled plasma, which had been shown to have a TAT 
concentration of 1.2 ~g/ml. 
Statistical Analysis 
Statistical analysis was performed using the NPARI WAY computer program 
of the Statistical Analysis SystemR (SAS Institute Inc., Cary, NC, U.S.A.). 
The significance of differences within and between groups were tested using 
the Wilcoxon rank-sum test and two-sample test respectively. Values for p < 
0.05 were considered to be significant. 
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RESULTS 
In all but one patient slightly to severely increased fibrinolytic activity, 
as measured by shortening of the euglobulin clot lysis time (ELT; normal 
> 120 min) or WBLT (normal >!50 min), was found in at least one blood 
sample during the operation. Signs of hyperfibrinolysis were most frequent at 
the end of the anhepatic stage and early after graft reperfusion of the 
donor liver. Fibrinolysis was defined as minimal if the ELT was longer than 
60 min or when the WBLT was longer than 90 min in all blood samples. 
Severe fibrinolysis was defined to be present when the ELT and WBL T were 
shorter than 60 and 90 min respectively, in at least one of the intraopera-
tive blood samples. According to these criteria the patients were divided into 
two groups. Group I was formed by 7 patients with minimal fibrinolysis. 
Group II consisted of 13 patients with severe fibrinolysis. Comparison of the 
preoperative hemostasis parameters showed 
the two groups (table 2). Both groups 
no significant differences 
included patients with 
between 
different 
diagnoses, without an accumulation of any diagnostic group in either one of 
the two groups. 
Mean intraoperative levels of t-PA activity and PAI activity of group I 
and II are depicted in figure 1. There were no significant changes in t-PA 
and PAl activity during the preanhepatic stage in both groups. In group I 
t-PA levels remained below 12 TIJ/ml during the rest of the operation in all 
patients. In group II t-PA activity increased after clamping of the vessels of 
the native liver and levels were significantly higher at the end of the 
anhepatic stage (111-5), compared with group I (p=O.OOZ). During reperfusion 
of the graft t-PA levels increased sharply, resulting in a more than doubling 
at 5 min after reperfusion, compared with the values at 5 mm before 
reperfusion (p< 0.007). At this time t-PA activity in group II (65.1±8.5 IU/ml, 
mean±SEM) was about 30 times higher than the preoperative value and more 
than 10 times higher than t-PA activity in group I (p=0.0004). Later in the 
postanhepatic stage a rapid disappearance of t-PA activity was seen and 
levels fell into the normal range (0-1 IU/ml) at the end of the operation in 
all but two patients. In these two patients t-PA levels were still moderately 
increased (3.4 and 10 IU/ml). In group II free PAl activity showed a pattern 
inverse that of t-PA activity and only minimal PAl activity (1.1±0.7 AU/ml) 
was left at the peak of fibrinolytic activity, but levels increased during the 
later postanhepatic period in both groups. 
Mean plasma levels of FbDP and FgDP in group I and II are shown in 
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figure 2. Although an increase of FbDP and FgDP was seen in both groups, 
levels in group II were significantly higher in the postanhepatic period at 45 
min after graft reperfusion when compared with group I (p<0.04). In group II 
the highest FgDP level (18.4±7.9 ~g/ml) coincided with the peak in t-PA 
activity (Il+5), whereas the maximum in FbDP (32.5±11.2 ~g/ml) occurred 
somewhat later in the postanhepatic stage (Ill+45). 
Table 2. Comparison of preoperative hemostasis profile in patients with 
minimal (group I) and severe (group II) intraoperative fibrino-
ly5is 
Variables 
Coagulation 
PT (sec) 
aPTI (sec) 
ThT (sec) 
Fibrinogen (mg/dl) 
* Factor II (%) 
* Factor VIII (%) 
TAT complex (~g/ml) 
Platelets (I o9 11) 
Fibrinolysis 
ELT (min) 
WBLT (min) 
t-PA act. (IU/ml) 
PAl act. (IU/ml) 
FgDP (~g/ml) 
FbDP (~g/ml) 
Reference 
values 
10.8-13.0 
26-34 
13-18 
150-450 
50-150 
50-150 
1.0-4.1 
150-450 
> 120 
> 150 
0-1.0 
0-40.0 
<0.5 
<0.5 
* % of pooled normal plasma 
** for all patients. 
Group I 
median (range) 
11.3 (10.4-21.2) 
36.0 (28.9-51.6) 
17.1 (15.3-32.9) 
285 (159-460) 
66 (32-130) 
185 (130-300) 
8.0 (2.0-16.0) 
81 (56-510) 
> 120 (105-> 120) 
> J5o** 
2.4 (0-6.0) 
18.5 (14.0-36.0) 
0.28 (0.20-3.0) 
0.30 (0.26-4.5) 
Group II 
12.2 (9.7-21.2) 
42.9 (29.1-127) 
22.0 (14.3-47.7) 
140 (85-350) 
38 (15-135) 
120 (82-280) 
4.3 (1.6-60.0) 
118 (39-336) 
60 (15->120) 
> 15o** 
1.4 (0-8.0) 
18.8 (3.0-37.5) 
0.50 (0.20-2.6) 
0.84 (0.22-6.0) 
Fig. I. 
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products (FgDP) and fibrin degradation products (FbDP) in 
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(stage II). 
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Mean levels of TAT complexes in group I and II are shown in figure 3. 
An identical increasing pattern was seen in both groups and at none of the 
time points were TAT levels significantly different between the two groups. 
Highest TAT levels were found during the postanhepatic stage and levels 
were still above the normal upper limit (>4.1 ~g/1) at the end of the 
operation in all patients. 
160 
TAT 
complex 140 
U9/i 
Fig.3. 
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Intraoperative levels (mean±SEM) of thrombin-antithrombin III 
(TAT) complexes in orthotopic liver transplantation. 0-0 ~ group 
1: patients with minimal fibrinolysis (n 7); ..._. ~ group II: 
patients with severe fibrinolysis (n = 13). Each tic on the abscissa 
indicates one hour. The area between the dotted lines represents 
the anhepatic stage (stage II). 
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Comparison of changes in arterial pH, p02 and blood pressure in group I 
and II are shown in table 3. There was no evidence for a relationship 
between intraoperative changes in hemodynamics and the increase in t-PA 
activity. Periods of shock, as detennined by a drop in blood pressure and 
pH were found among both patients with high and low t-PA activities. 
The intraoperative use of blood products is shown in table 4. There were 
no differences in the use of cryoprecipitate and platelets between the two 
groups. However, intraoperative blood loss, as reflected by the total use of 
modified whole blood or packed RBC and fresh frozen plasma, was signifi-
cantly higher in group II than in group I (p<0.02). 
Table 3. Comparison of intraoperative hemodynamic changes in patients 
with low (group I) and high (group II) t-PA activity 
Hemodynamics at the end of stage II 
Arterial pH 
Arterial p02 (mm Hg) 
Number of patients with 
a hypotensive period 
Hemodynamics early in stage III 
Arterial pH 
Arterial p02 (mm Hg) 
Number of patients with 
a hypotensive period 
pH and P02 are expressed in median (range) 
Group I (n= 7) 
7.37 (7.33-7.45) 
2I8 (113-311) 
In (I4%J 
7.31 (7.22-7.42) 
272 (I50-486) 
In (14%) 
Group II (n=I3) 
7.40 (7.34-7.46) 
279 (I22-397) 
3!13 (23%) 
7.32 (7.I5-7.42) 
275 (114-531) 
5/I3 (38%) 
Table 4. 
RBC* (U) 
FFP (U) 
RBC+FFP (U) 
Ill 
Intraoperative blood use in patients with low (group I) and 
high (group II) t-PA activity. 
Group I (n= 7) Group II (n=l3} 
mean 5 19 
median (range) 4 (1-8) 10 (3-101) 
mean I 11 
median (range) 0 (0-8) 4 (0-68) 
mean 6 30 
median (range) 4 (2-16) 10 (3-169) 
Cryoprecipitate (U) mean o •• 3 
median (range) 0 0 (0-12) 
Platelets (U) mean 3 5 
median (range) 0 (0-10) 8 (0-28) 
* RBC includes packed red blood cells and modified whole blood. 
** for all patients. 
DISCUSSION 
In earlier 
measured by 
the patients 
studies we have found that increased fibrinolytic act1v1ty, as 
the ELT or thrombelastography (TEG}, occurs in about 80% of 
undergoing orthotopic liver transplantation (18,25). Fibrinolytic 
activity may increase during the anhepatic stage and is most often severe 
early after graft recirculation. A simultaneous decrease of plasminogen and 
a 2-antiplasmin, the main inhibitor of plasntin, has been found during this 
period, which supports the view of an active fibrinolytic process (5). 
However, the use of ELT and TEO in these studies did not allow an exact 
characterization of the fibrinolytic defect, and the origin and clinical 
relevance of the increased fibrinolytic activity have remained largely unclear. 
In this study we found an extreme increase of t-PA activity, and 
concomitant decrease of PAl activity during the anhepatic and early ostan-
hepatic period in patients with severe fibrinolysis, as measured by the ELT 
and TEG. Reduction in PAl activity can be explained by the formation of 
complexes with t-PA. After saturation of free PAl, a further increase of t-
PA will result in the increase of free t·PA activity in the circulation (9,21). 
Recently, Dzik et 
increase of t-P A 
undergoing OLT. 
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a! (6) and Palareti et a! (7) 
during the anhepatic stage in a 
However, these studies did not 
have reported a similar 
limited number of patients 
show the explosive t-PA 
increase, occurring directly after graft reperfusion, as seen in our patients. 
Since we observed a rapid normalization of t-PA activity after its maximum, 
this peak could have been easily missed in the other studies if no blood 
samples were taken within 10 minutes after reperfusion. 
The intraoperative course of t-PA activity suggests that there are two 
different mechanisms responsible for the increase of t-PA during orthotopic 
liver transplantation. The initial rise of t-PA during the anhepatic stage has 
been explained by a combination of increased release of t-PA and reduced 
hepatic clearance (6). This view is supported by the lack of fibrinolytic 
activation during auxiliary, heterotopic liver transplantation in which the 
native liver is not removed (26,27). Dzik et al. (6) found that increase of t-
PA during orthotopic liver transplantation may be associated with 
shock. They suggested a mechanism of increased t-PA release due 
signs of 
to hypo-
tension and acidosis. We could not find any differences in blood pressure, 
arterial pH or p02 in patients with high or low t-PA levels. Probably other 
mechanisms than changes in the arterial circulation may also attribute to an 
increased release of t-PA. Patients with liver disease are known to be prone 
to activation of their fibrinolytic system upon specific stimuli as physical 
stress and exercise (28,29). The surgical stress, with the manipulations and 
extensive trauma to the vascular bed and abdominal circulation, therefore, 
might have contributed to an increased release of t-PA. 
The rapid increase during graft reperfusion suggests a second mechanism 
which is associated with the restoration of blood flow through the donor 
liver. In studies with pigs we recently demonstrated that fibrinolytic 
activity in the hepatic venous outflow immediately after graft reperfusion is 
significantly higher than the fibrinolytic activity in the systemic circulation 
(Porte et a!, 1988. unpublished data). These data, in combination with the 
"explosive" t-PA increase after reperfusion in this study, strongly suggest an 
increased release of t-PA from the reperfused donor liver. Several factors, 
including vasoreactive agents, venous occlusion, anoxia and thrombin have 
been found to stimulate t-PA release from endothelial cells in in vitro and in. 
vivo studies (8,30,31). It can be theorized that, during graft reperfusion and 
the subsequent restoration of normal portal blood flow, one or more of these 
factors, or leakage from ischemic damaged endothelial cells, contribute to an 
increase of t-PA. The normalization of t-PA activity during the late postan-
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hepatic stage can be explained by the restoration of the normal hepatic 
clearance of t-PA after the implantation of a viable donor liver. Reduction 
of t-PA activity might have been enhanced by an increase of PAl towards 
the end of the operation, which is generally seen after major surgery and 
which is consistent with the behavior of PAl as an acute phase reactant 
(32). 
Some investigators have 
liver transplantation may 
(7 ,11). For several reasons 
be 
suggested 
secondary 
that hyperfibrinolysis 
to thrombin formation 
in orthotopic 
during DIC 
we do not believe that DIC is the main cause of 
t-PA increase during orthotopic liver transplantation. 
First of all, in large series of patients, we previously found no evidence 
for a combined decrease of coagulation factors and inhibitors, as occurs 
during DIC (24,33). Repeatedly negative findings regarding thrombo-embolic 
processes in histopathologic and clinical examination support the view that 
DIC does not play a clinically important role in OLT (34,35). 
Secondly, this study provided evidence for a thrombin independent 
increase in t-PA 
which are formed 
between thrombin 
during liver 
early during 
transplantation. Although 
clotting activation by 
and antithrombin 111 (24), increased 
TAT 
complex 
steadily 
complexes, 
formation 
from the 
beginning of the operation and were still elevated at the end of the 
operation, t-PA increase was clearly limited to the 
postanhepatic stage. Additionaly, there was no difference 
anhepatic 
in TAT 
and early 
increase in 
patients with high or low t-PA levels, indicating that the t-PA increase was 
independent of thrombin formation. The rise in TAT levels in our patients 
was most probably a sign of local clotting activation at the wound surface. 
Further studies, preferably with patients undergoing other major abdominal 
surgical procedures as control group, however, are necessary to establish the 
role of increased TAT levels in orthotopic liver transplantation. 
Thirdly, secondary fibrinolysis during DIC is probably a more local 
process which does not result in detectable increased fibrinolytic acuvlty in 
the systemic circulation. In an analysis of 346 patients with DIC, Spero et 
al. (36) found evidence of systemic fibrinolytic activation, as demonstrated 
by shortened ELT or recalcified clot lysis time, in only 10% of the patients. 
Francis and Seyfert (37) recently demonstrated that although t-PA antigen is 
elevated in patients with DIC, detectable free t-PA activity is less frequently 
present than in hospitalized controls. These investigators concluded that PAl 
levels are also increased in DIC, leading to masking of the increased 
endothelial secretion of t-PA. This view is supported by experiments with 
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cultured endothelial cells in which thrombin was shown to stimulate the 
release of both t-PA and PAl (30), resulting in no detectable net free t-PA 
activity 
systemic 
resulting 
despite increased levels of t-PA antigen. We observed a 40-50 fold 
increase of t-PA activity and a concomitant saturation of PAl, 
in a decrease of free PAI activity during the period of hyper-
fibrinolysis. Another process than DIC, therefore, seems responsible for the 
increased t-PA activity in orthotopic liver transplantation. Why some patients 
develop a high increase of t-PA activity, whereas others do not, remains 
unclear. We could not find any difference in diagnosis, preoperative hemosta-
sis profile or intraoperative hemodynamics in patients with high or low 
intraoperative t-PA activity levels. 
Irrespective of its origin, the extremely high t-PA levels during the 
early postanhepatic stage may be clinically important. Especially in this 
period, formation of fibrin and stable hemostatic clots is necessary to 
prevent or stop bleeding from the vascular anastomosis and the extensive 
wound surface. Although the systemic increase of t-PA activity had a 
transient character, the clinical effect may extend over a considerably 
longer period, as t-PA may bind to fibrin and become incorporated in newly 
formed hemostatic clots, resulting in early lysis and delayed bleeding from 
fresh wounds (38). The role of t-PA in the development of a systemic lytic 
state was demonstrated in this study by the increase of plasma levels of 
both FbDP and FgDP in patients with high t-PA levels. This confirms earlier 
studies, which suggested a plasmin-mediated destruction of coagulation 
factors during orthotopic liver transplantation (5,33). FgDPs are known to 
have an anticoagulant effect by inhibiting the polymerization of fibrin 
monomers into crosslinked fibrin (39). The occurrence of FgDPs in the 
circulation, therefore, may well be attributed to a further deterioration of 
the hemostatic function in patients 
tation, as has been suggested before 
undergoing 
by Blecher 
orthotopic liver transplan-
et al. (40). The peak of 
FbDPs in the early postanhepatic stage is consistent with the clinical picture 
of delayed oozing and increased blood loss in this period (18,25). We indeed 
found an significantly higher blood loss in patients with severe fibrinolysis 
(group II). However, these data should be interpreted with some reserve, as 
blood loss is influenced by multiple factors and larger series of patients are 
necessary to confirm this observation. 
Since the primary increase in t-PA activity was associated with an 
active proteolytic destruction 
the use of antifibrinolytic 
of fibrinogen and fibrin and a high blood 
drugs seems justified in patients with 
loss, 
life 
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threatening hemorrhages where active fibrinolysis is likely. To identify these 
patients, it is advisable to include at least one test method for the assess-
ment of fibrinolytic activity in the intraoperative hemostasis monitoring in 
orthotopic liver transplantation. 
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SUMMARY 
Coagulation and 
during and after a 
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fibrinolysis parameters were 
case of auxiliary partial liver 
extensively monitored 
transplantation (APLT). 
Preoperative coagulation tests demonstrated a severe liver dysfunction. 
Routine coagulation tests were prolonged and low levels of fibrinogen, 
antithrombin III (AT-Ill), and az-antiplasmin (az-AP) were measured. Pro-
urokinase (pro-Uk), total Uk-antigen and plasminogen activator inhibitor 
(PAl) activity were increased (6.2; 5.4 ng/ml and 12.5 IU/ml, respectively). 
During transplantation no major changes in hemostasis were detected by 
either standard coagulation tests or thrombelastography and only minimal 
increase of fibrinogen degradation products (0.6-1.0 ~g/ml) was seen just 
before graft recirculation up till the end of the operation. PAl levels 
remained high during the operation and neither tissue-type plasminogen 
activator (t-PA) nor active urokinase (u-PA) were detectable. After APLT, 
graft function was reflected by normalization of coagulation parameters and 
increase of AT-Ill and az-AP to normal levels. Pro-Uk and PAl activity 
levels decreased after transplantation to normal values; a transient increase 
of t-PA activity (max. 1360 miU/ml) was seen from the tenth to nineteenth 
day. It was demonstrated that a heterotopically placed liver allograft can 
provide synthesis of hemostasis factors and inhibitors and restore clearance 
which is adequate to reverse coagulopathy. 
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INTRODUCTION 
Liver transplantation, which began as 
years ago, has reached such a high level of 
highly experimental surgery 20 
success that it is now recognised 
liver disease (1). as a major means of therapy for patients with end-stage 
The most commonly performed 
which the diseased host liver 
liver transplantation (OLT) in 
bleeding tendency which is 
mortality (2,3). Auxiliary liver 
technique is an 
is replaced by 
orthotopic transplantation by 
a liver allograft. Orthotopic 
humans is often complicated by a severe 
associated with a marked (post-) operative 
transplantation is a different technique by 
which a liver graft is transplanted in a heterotopic position without removal 
of the diseased host liver. Theoretically, auxiliary liver transplantation would 
be expected to have a reduced bleeding tendency, because the surgical 
trauma is less and the patient's own liver retains the ability to produce 
clotting factors and remove procoagulant factors from the circulation. After 
extensive experimental studies with auxiliary liver transplantation in animals 
( 4-6), an auxiliary partial liver transplantation (APLT) program for humans 
has been started in the University Hospital of Rotterdam in cooperation with 
the University Hospital Leiden and the Municipal Hospital of Amhem, The 
Netherlands in 1986. In this paper we report the results of monitoring 
coagulation and fibrinolysis parameters during and after APLT in the first 
case. Details of the surgical procedure will be described elsewhere. 
METHODS 
During transplantation and in the first 3 postoperative days, blood 
samples were taken from an arterial line. (The first 10 ml were discarded to 
flush traces of heparin from the line). During the further postoperative 
course blood was collected by venapuncture with minimal stasis. Blood was 
collected into polystyrene test tubes, contammg ml ice-cold trisodium 
citrate 0.11 mol/1 (9 val + 1 val), immediately placed on melting ice and 
centrifuged (2800g, 4°C, 30 min) within 20 min. Plasma was collected at 4°C, 
snap-frozen and stored in small aliquots at -70°C until used. A few ml of 
blood were also collected in a 
thrombelastographic monitoring. 
intervals during transplantation: 
plastic syringe and used within 3 min for 
Blood samples were obtained at various 
directly after induction of anaesthesia, 
thereafter every 1.5 h; 5, 15 and 30 min after reperfusion of the liver graft 
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and thereafter every hour. During the first postoperative weeks blood 
samples were taken daily between 8:00 and 11:00, with exception on days 1 
and 8 when blood samples were taken at 16:00 and 14:30, respectively. 
Routine coagulation tests were performed using standard techniques. 
Antithrombin III (AT-III) activity was measured according to Abildgaard et al 
(7) using CoatestR antithrombin (Kabi Yitrum BY, Amsterdam, The Nether-
lands) (Normal values: 0.70-1.28 U/ml), o:rantiplasmin (a2-AP) was assayed 
according to Friberger et al (8) using CoatestR antiplasmin (Kabi Yitrum BY). 
a2-AP antigen was assayed by Rocket immunoelectrophoresis according to 
Lauren (9), using a 1.5% rabbit anti a 2-AP antiserum (batch 31-1085) 
obtained from Nordic Immunology, Tilburg, The Netherlands (N: 80-140%). The 
ratio of the two molecular forms of o:rAP, the plasminogen binding (PB) and 
the non-plasminogen binding (NPB) form, was determined by modified crossed 
immunoelectrophoresis as described by Kluft & Los (10) (N: 2.1-2.8). Fibrino-
gen was measured according to Clauss (11) (N: 1.2-4.8 g/1). Three different 
sandwich-type enzyme immune assays (EIA), based on monoclonal antibodies, 
were used for the separate quantitation of fibrinogen degradation products 
(FgDP) (12), of fibrin degradation products (FbDP) (13), and the total of 
FgDP and FbDP (TDP-assay) (14) (N: <0.5 ~g/ml). Fibrinolytic activity of the 
euglobulin fraction of plasma was measured as the euglobulin clot lysis time 
(ECLT). Standard euglobulin fractions of plasma were prepared at pH 5.9 
with a plasma dilution of 1:10 (15). Precipitates were redissolved m 
Tris/Tween buffer (O.lM Tris/HCL, containing 0.1% Tween 80 (v/v) pH 7.5) 
and to 0.2ml aliquots of the dissolved euglobulin fractions 0.1 ml portions of 
calcium-thrombin solution (CaC12 25 mmol/1 and thrombin 10 NIH U/1) were 
added to induce clot formation. The lysis of the clot was recorded. The 
disappearance of air bubbles was regarded as the endpoint of lysis. Tissue-
type plasminogen activator (t-PA) activity and plasminogen activator 
inhibition (PAl) activity were measured by spectrophotometric assays 
according to Verheijen et al {16,17). Total urokinase-type plasminogen 
activator antigen (Uk-Ag) was assayed by EIA (18) (N: 2.1-4.9 ng/ml), active 
urokinase (u-PA) antigen and pro-urokinase antigen were assayed by a 
biological immuno assay (BIA) (19) (N; 1.7-2.5 ng/ml). The activity of whole 
blood coagulation and fibrinolysis, including cellular and humoral elements 
such as interactions of red blood cells, platelets, coagulation and fibrinolysis 
factors, and calcium were recorded by Thrombelastography (TEG), using 
whole blood (20). Blood (0.36 ml) was placed in the Thrombelastograph 
(Hellige Company, Freiburg, FRG) and two drops of paraffin oil were spread 
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over the blood surface to prevent evaporation. Recording was started 2-3 
min after the blood sampling time. The TEO repeatedly measures the shear 
elasticity of a blood clot from the time when the first fibrin strands are 
formed to the completion of the clot formation, including fibrinolysis. The 
following variables were measured: reaction time (r-value), clot formation 
time (k-value), maximum amplitude (MA) and whole blood clot lysis. 
RESULTS 
Case Report 
A 36-year-old white male, known to have chronic persistent hepatitis B 
since 1976, developed liver cirrhosis. He had two periods of hepatic coma 
due to a severe liver cirrhosis in 1985 and 1986. At those times active viral 
replication was no longer detectable. After having been accepted as the first 
patient in our auxiliary partial liver transplantation program he was admitted 
in coma (grade IV, encephalopathy) caused by a change in diuretic treatment 
for ascites. He was treated with lactulose. and neomycin for encephalopathy, 
regained consciousness and was placed on the urgent list for transplantation. 
He underwent an APLT on October 23, 1986. After resection of the lateral 
segment of the left liver lobe, the graft was placed in the upper right 
abdominal cavity. The suprahepatic vena cava of the graft was anastomosed 
to the recipient infrahepatic vena cava, the portal vein of the graft was 
anastomosed end-to-side to the portal vein and the hepatic artery with an 
oval aorta patch was anastomosed end-to-side to the infrarenal aorta. 
The patient received a fixed loading dose of blood products during the 
anaesthesia induction. This consisted of fresh frozen plasma (FFP) (550ml), 
cryoprecipitate (4x250 U factor-VIII) and platelets concentrates (16 donor 
units). Further supplements of blood products during the operation are shown 
in figure lA, IB and 2A. During the APLT, which lasted for almost 7h, II 
FFP, 4x250 U F-VIII cryoprecipitate and 16 donor units of platelet con-
centrates were given, in addition to the loading dose. The total red blood 
cell (RBC) supplement during the whole transplantation was 4.5 I. 
The postoperative course was uncomplicated, except for a small rise of 
creatine and bilirubin with a maximum on the fourth postoperative day. One 
generalized epileptic attack occurred as a result of low plasma levels of 
phenobarbital on the fourth postoperative day (the patient was known to 
have primary grand mal epilepsy from the age of 14 years). From the first 
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postoperative day, the patient was treated prophylactically with a low dose 
unfractioned heparin i.v. (12,000 IU/24h), later followed by oral anticoagulant 
therapy for 3 months. 
Four weeks after APLT, the patient was discharged from our hospital in 
good condition. During his regular visits to the out-patient clinic, he 
showed further improvement until the present-time, 8 month after trans-
plantation. 
Hemostasis Study 
Preoperative hemostasis parameters were stable at reduced levels for 
months. The values just before transplantation were: prothrombin time (PT) 
21 sec (N: 10-14 sec), thrombin time (THT) 21 sec (N: 10-15 sec), activated 
partial thromboplastin time (APTT) 51 sec (N: 22-37 sec), fibrinogen level 1.0 
g/1, AT -III activity 0.28 U/ml, platelet count 31 xI 09/1 (N: !40-320x 109 /1), o:2-
AP activity 0.33 U/ml and antigen level 44%, with a PB:NPB ratio of 1.4. 
PAl, Uk-Ag and pro-Uk plasma levels were 12.5 IU/ml, 6.2 and 5.4 ng/ml, 
respectively. No t-PA activity, or active u-P A were detectable. 
Intraoperatively, TEG monitoring showed no major changes in coagulation, 
or enhanced fibrinolytic activity (Fig. 3.). The individual hemostasis para-
meters measured during the operation are shown in Figures IA and B. A 
prolongation of the APTT was seen after recirculation of the graft (Fig. 
IA), but it had returned to the preoperative value before the end of the 
operation. During surgery, PAl levels were > 25 IU/ml and neither t-PA nor 
active u-PA were detectable. FbDP and TDP levels fluctuated between 1.4-
3.6 ).lg/ml and 2.0-5.1 ).lg/ml respectively, without showing acute changes. 
FgDP reached detectable levels just before recirculation of the graft (0.6 
IJ-g/ml) and showed a minimal increase up to the end of the operation (1.0 
).lg/ml). 
Postoperatively, APTI, PT and THT, as well as fibrinogen plasma concen-
trations stabilized at normal levels during the first days (data not shown). 
AT -III and a TAP plasma levels on the days after transplantation are shown 
in Figure 2A. From the first day an increase of both AT-III and 0:2-AP 
plasma levels was seen and normal levels were reached on the third and 
second day respectively. The ratio of the PB:NPB forms of o:2-AP, measured 
on the nineteenth day was significantly higher as compared with the 
preoperative ratio (2.9 and 1.4, respectively) (Fig. 2B). Levels of plasminogen 
activators, ECLT and platelet count are shown in Figure 4. Enhanced 
fibrinolytic activity was demonstrated by lysis on TEG and shortened ECLT 
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from the tenth to the nineteenth day. On these 
increased reaching a maximum 
decreased immediately after 
days, t-PA activity was 
of 1360 miU/ml on the 
the transplantation and 
found to be 
tenth day. 
greatly 
Pro-Uk 
reached normal values at the end of the second week. PAl remained high 
during the first day (12.5 IU/ml) but declined thereafter to 2.5 IU/ml on the 
fifth day. From the first day on FgDP were no longer detectable. FbDP 
levels decreased slowly, but remained detectable at a low level (1.0-2.7 
)lg/ml) until 25 days after transplantation. 
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A rise of the PB form of a 2-AP (synthesized by the liver) was demonstrated by a higher ratio of the PB:NPB forms on the 
nineteenth day, in comparison with the preoperative sample. The 
PB:NPB ratios determined by crossed immunoelectrophoresis of 
plasma were 2.9 and 1.4 respectively (normal range: 2.1-2.8). 
Fig.3. 
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DISCUSSION 
Massive blood loss and disturbances of hemostasis are still major problems 
during orthotopic liver transplantation. Most changes are seen during the 
anhepatic phase and after reperfusion of the liver allograft (21-23). At these 
times a serious coagulopathy is seen, which is due to reduced function of 
clotting factors, including fibrinogen, and of platelets, in combination with 
an increase of fibrinolytic activity. Auxiliary liver transplantation has been 
demonstrated in experimental studies in animals to be associated with less 
surgical trauma. with only minor changes in hemodynamics, and with less 
intraoperative blood loss (24). The lack of an anhepatic phase probably 
contributes to the fact that the major disturbances in hemostasis seen during 
OLT are less extensive in APLT. In this paper we report the results of both 
intraoperative and postoperative monitoring of several coagulation and 
fibrinolysis parameters in the first patient of our APLT-program. 
Preoperatively, the hemostasis profile of the patient reflected 
liver cirrhosis with severe dysfunction including prolongation of 
coagulation tests and low individual hemostasis factors. 
end-stage 
standard 
Intraoperatively, only minor changes in hemostasis were detected which 
was probably partly due to the supplement therapy. Even after reperfusion 
of the liver graft no serious changes in hemostasis were seen. The lack of 
an anhepatic phase probably contributed to prevent deterioration of the 
pre-existing coagulopathy. 
Postoperatively, normalization of the coagulation function tests (APIT, PT 
and THT) as well as fibrinogen concentration indicated that the liver 
allograft synthesized sufficient clotting factors to reverse the coagulopathy. 
The synthetic activity of the liver allograft was demonstrated by the rise of 
AT-Ill and o:2-AP levels and increase of the ratio PB:NPB forms of a 2-AP. 
Recently it was demonstrated that the very active PB form of a 2-AP, which 
is synthesized by the liver, is converted m the circulation into the less 
active NPB form (25). Enhanced synthesis of az-AP therefore results in a 
temporary increase of the PB:NPB ratio. The early rise of az-AP, i.e. before 
AT-III, is compatible with the acute phase reacting properties described for 
this protein (25). 
Our observations on PAl and pro-Uk deserve special comment. The 
increased levels of PAl and pro-Uk before transplantation are consistent 
with the high levels found in patients with severe liver dysfunction by 
other investigators (26, 19). Although it has been suggested that this is due 
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to a decreased clearance by the diseased liver, the mechanism of the 
increase in these factors is still unclear. In our patient, levels of PAl 
remained high during the first day after transplantation, which is also 
found in other types of surgery (27), and is ascribed to its acute phase 
reactant properties. The decrease of pro-Uk levels immediately after APLT, 
strongly suggests a role of the liver in the clearance of pro-Uk from the 
blood. 
Although pro-Uk further declined to normal levels during the postopera-
tive period, a transient rise of the other plasminogen activator, t-PA, was 
seen from the tenth to nineteenth day. A mild degree of activation of 
fibrinolysis after an auxiliary liver transplantation has also been described by 
Howland et al (28). However, this occurred during the first 3 days after 
transplantationand the cause of this phenomenon also remains unclear. 
Since our findings are based on only one patient it may be premature to 
draw general conclusions on the influence of APLT on hemostasis. We 
believe. however, that this case shows that a heterotopically placed partial 
liver allograft can synthesize hemostasis factors sufficiently well to reverse 
the coagulopathy. Whether hemostasis will remain as stable during and after 
APLT in our next patients remains to be seen. Apart from this direct patient 
care, extensive monitoring provides the opportunity to study the role of the 
liver in the synthesis and clearance of several coagulation and fibrinolysis 
factors. 
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SUMMARY 
Orthotopic liver 
disturbances and a 
increased, especially 
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transplantation (OL T) is 
severe bleeding diathesis. 
during the anhepatic 
associated with haemostatic 
Fibrinolytic activity may be 
phase and after graft-
recirculation and this has been mentioned as a possible causative factor in 
the occurrence of uncontrollable bleeding. However, most studies were based 
on global assays and could not clarify the origin of the increased fibrino-
lysis. Recently, a programme of auxiliary liver transplantation (APLT) was 
started in Rotterdam. APLT is a surgically less traumatic procedure in which 
no anhepatic phase occurs. We examined fibrinolytic activity in the first 8 
cases of APLT by thrombelastography (TEG), and also by measuring plasma 
levels of tissue-type plasminogen activator activity (t-PA-act) and antigen 
(t-PA-Ag) and its inhibition (PAl). Intraoperatively, in only two of the eight 
APLTs, a period of enhanced fibrinolytic activity was observed on TEO-
recordings. This could be explained by an increase of t-PA-act (max. 8840 
m!U/ml and 3760 m!U/ml) and t-PA-Ag (2: 60 ng/ml). Both patients had signs 
of increased bleeding during these periods. Postoperatively, in patients with 
a good graft function PAl levels decreased to normal values, whereas persis-
tently elevated PAl levels (2: 25 IU/ml) were found in cases with primary 
non-functioning liver grafts. 
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INTRODUCTION 
Orthotopic liver transplantation (OLT) 
loss1, which is correlated with a high 
is associated with massive blood-
perioperative mortality2. In the first 
report 
cause 
of the European Liver Transplant Registry, haemorrhage was the main 
of death (34%) during the first 7 postoperative days3 Although the 
number of transplants the world over is doubling annually, the etiology of 
this bleeding diathesis is still not fully elucidated and can only be partially 
explained by the surgical trauma and changes that occur in the haemostatic 
mechanism. 
Increase in fibrinolytic activity has been reported in liver transplantation 
and it has been mentioned as a possible causative factor in the occurrence 
of uncontrollable bleeding4•5. However, since most studies were based on 
global assays for determination of fibrinolytic activity, they could not clarify 
the origin of the increased fibrinolytic activity. From recent insights m 
fibrinolysis, we know that increased fibrinolysis may be caused by an 
increase in plasma levels of tissue-type plasminogen activator (t-PA), which 
itself was found to be associated with a haernorrhagic diathesis6. Specific 
assays for the determination of both t-PA and plasminogen activator 
inhibition (PAl) in plasma have been developed and we are now able to 
investigate the role of these factors m the origin of increased fibrinolytic 
activity in liver transplantation. 
A program of auxiliary partial liver 
with severe liver disease was started 
1986. Heterotopic transplantation of an 
transplantation (APLT) in patients 
in Rotterdam, The Netherlands, in 
auxiliary liver-graft is a surgically 
less traumatic procedure than OLT and it is not attended with an anhepatic 
phase 7. Since clearance and synthesis of plasmatic factors of coagulation and 
fibrinolysis may still be possible at a low level throughout the whole 
operation, changes in haemostasis may be less prominent8. 
The aim of this study was to examine whether changes in the fibrino-
lytic system, as found by thrombelastographic monitoring during OLT9, do 
also occur during APL T and if so, whether these can be explained by 
changes in plasma levels oft-PA. 
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PATIENTS AND METHODS 
Patients 
Between October 1986 and November 1987, 8 APLTs were performed in 7 
patients, one of whom required retransplantation during this period. In four 
patients the indication was an end-stage of chronic liver disease and the 
diagnosis acute hepatic failure (AHF) was made in the other cases (including 
one retransplantation). Heterotopic transplantation of an auxiliary partial 
liver graft was performed essentially as described before in animal studieslO_ 
Technical details of the procedure and clinical course will be described 
elsewhere. 
Fibrinolysis study 
Blood samples were drawn from an arterial line during the operation and 
in the first postoperative days and by venapuncture in the later postopera-
tive period. Blood (9 ml) was collected in 1 ml ice-cold trisodium citrate 0.11 
mol/1, immediately placed on melting ice and centrifuged (2800 g, 4'C, 30 
min) within 20 min. Plasma was collected at 4•c, snap-frozen and stored in 
small aliquots at -70"C until used. Blood samples were taken at various 
intervals during transplantation: directly after induction of anaesthesia, 
thereafter every 1.5 hr; 5 min before recirculation, 15, 30 and 60 min after 
recirculation of the liver-graft and every hour thereafter. Postoperative 
bloodsamples were taken daily between 8:00 and 10:00 hrs. 
The thrombelastographic (TEG) registration of whole blood coagulation and 
fibrinolysis was performed by using a Thromb-Elastograph-D (Hellige 
Company, Freiburg, FRG), The whole blood clot lysis index was calculated 
as the ratio of the maximum amplitude (MA) of the TEO-recording and the 
amplitude 60 min after MA (A~0), (A60·'MA x 100%). Fibrinolytic activity 
was defined as a clot lysis index ,; 80% . 
Tissue-type plasminogen 
activator inhibition (PAl) 
(reference values: 0-200 
activator activity (t-PA-act) and 
were assayed according to Verheijen 
m!U/ml and 0-25 IU/ml, respectively). 
plasminogen 
et alll,l2 
Tissue-type 
plasminogen activator antigen (t-PA-Ag) was measured by using an enzyme 
immuno assay (Biopool IMUL YSE ™ 5-t-PA) 13 (reference values: 5-10 
ng/ml)13 In this assay, both free t-PA and t-PA in the inactive complex 
form with PAI, are measured. 
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RESULTS 
Preoperative period 
Preoperative TEG was performed in 5 cases (APLT 3,4,5,7 and 8), none of 
which demonstrated fibrinolytic activity (figure 1). No t-PA-act was detec-
table in the preoperative plasma sample in 6 cases, while t-PA-act (1200 
miU/ml) was increased in one patient with AHF. Median preoperative t-PA-
Ag level was 33 ng/ml (range 18-55 ng/ml) and PAl was 14 IU/ml (range 
1.2->25 IU/ml). 
Intraoperative period 
Intraoperatively, two different patterns of TEG recordings could be 
distinguished, demonstrating either an absence 
activity (pattern A) or a periodical increase of 
B). 
of significant fibrinolytic 
fibrinolytic activity (pattern 
Pattern A, without any signs of fibrinolysis (clot lysis index >80%), was 
observed in 6 cases of APLT (figure 1). During these transplantations PAl 
levels increased and remained elevated (~25 ill/ml), and t-PA-act was either 
undetectable or very low (:>80 miU/ml). Levels of t-PA-Ag showed no major 
changes during these operations. In figure 2 the data of two representative 
patients from this group are depicted. 
Pattern B, with increased fibrinolytic activity (clot lysis index :::;80%), was 
found in two patients. The period of increased fibrinolytic activity occurred 
in the period before graft-recirculation in one patient (APLT 5, clot lysis 
index 56% and 23%) and 1 hr after recirculation in the second patient (APLT 
7, clot lysis index 0%) (figure 1). High levels of t-PA-act (max 8840 miU/ml 
and 3760 m!U/ml) were measured in these periods (figure 3). Increased t-PA-
act coincided with a fast rise of t-PA-Ag and a concurrent reduction of PAL 
The increase in t-PA-act lasted for 3 to 3.5 hrs and was self-limiting. 
During this period, both patients suffered high bloodless due to generalized 
oozing from the surgical field. 
Fig. 1. 
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auxiliary liver 
was demon-
recirculation 
was found 
Thrombelastographic recordings in eight cases of 
transplantation (APLT). Increased fibrinolytic activity 
strated before graft recirculation in APLT 5 and after 
in APLT 7 (pattern B, see text). No fibrinolytic activity 
in the remaining cases (pattern A, see text). 
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Fig. 2. Intraoperative plasma levels of t-PA-act, t-PA-Ag and PAl in two 
representative cases of auxiliary liver transplantation, without signs 
of fibrinolysis (APLT 1 and 6). t-PA-act was either undetectable or 
very low, while PAl levels increased and remained high during the 
operation. 
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Intraoperative plasma levels of t-PA-act, t-PA-Ag and PAl in two 
cases of auxiliary liver transplantation (APLT 5 and 7) with In-
creased fibrinolysis on thrombelastographic recordings. t-PA-Ag 
levels in APL T 5 were always <: 60 ng/ml. 
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Postoperative period 
Postoperatively, PAl levels also showed two patterns. Either a decrease 
to normal values or a persistent high level of PAl was found. A decrease of 
PAl to normal values below 25 IU/ml was found in four patients with a 
good graft function (figure 4). Persistent elevated levels of PAl (>25 IU/ml) 
were measured in three cases that were complicated by primary non-function 
of the graft. t-PA-act was almost always undetectable, in spite of the 
relative high levels of t-PA-Ag in these patients (figure 5). A postoperative 
period with enhanced fibrinolysis on TEG was found in two patients at the 
end of the first and second week and this was also correlated with increased 
levels of t-PA-act and t-PA-Ag14 
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Fig. 4. 
~ 
tPAact 
60 2400 miUfml 
" 
1600 ~ 
' 
2:"~ 800 V.N\... O'"Q~ ~:[).(1 ~ 0 25 
" 
" 
8 
0 
\J 
o 4 a 12 rs 20 o 4 a 12 rs 20 o 4 a 12 rs 20 o 4 a 12 rs 20 
days days days days 
APLT 1 APLT 3 APLT 4 APLT 6 
Postoperative plasma levels of t-PA-act, t-PA-Ag and PAl in four 
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DISCUSSION 
Increase m fibrinolytic activity was already observed during the first 
human liver transplantations in the sixties 15 and has been reported by 
several investigators later4•5. Haemostatic disorders were found to be most 
significant during the anhepatic phase and to deteriorate upon graft-recir-
culation. However, until now all studies were based on global assays for the 
overall detection of fibrinolytic activity, such as the euglobulin clot lysis 
time and TEG and the origin of this increased fibrinolysis is still unclear. In 
recent years, knowledge of the fibrinolytic system has greatly increased and 
we now know that high plasma levels of t-PA may cause enhanced fibrino-
lytic activity, associated with a bleeding tendency6. Since t-PA is produced 
by endothelial cells and cleared from the circulation by the liver16, it may 
be hypothesized that fibrinolysis during OLT is caused by a diminished 
clearance of t-PA during the anhepatic phase or release from ischaemically 
damaged graft-endothelial cells after recirculation. However, plasma levels of 
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these factors during liver transplantation have not been reported. Further-
more no data are available on the occurrence of increased fibrinolytic 
activity during APLT, a technique of liver transplantation in which no 
anhepatic phase occurs10. 
In this study we observed increased fibrinolytic activity during the 
operation in only two of the eight cases of APLT. This increased activity, 
detected by TEG, could be explained by a sharp increase of t-PA-act. 
During the other 6 operations moderate amounts of t-PA-Ag were detectable 
in plasma, but this did not result in measurable levels of t-PA-act since 
plasma levels of PAl were high in these cases. It can be concluded that 
most t-PA was present in the inactive complex form with PAl. From figure 3 
it may be concluded that the increased t-PA-act in APLT 7 was caused by a 
sharp increase of t-PA-Ag, to such high levels that the excess PAl could be 
overcome. Since in APL T no an hepatic phase occurs, the increase in fibrino-
lytic activity, observed in these operations is unlikely to be caused by a 
diminished clearance of plasminogen activators but is probably due to an 
increased release of t-PA into the circulation. 
In the postoperative period we found that in patients with a good graft 
function, PAl levels decreased to normal values, while persistent high levels 
were found in cases with a primary non-functioning liver graft. These high 
levels 
failure 
of PAl may 
or may be 
condition. 
be due to disminished hepatic clearance during graft 
an expression of general deterioration of the patient's 
In summary we can state that increased fibrinolysis was found by TEG 
in only two of the eight cases of APL T. Enhanced fibrinolytic activity can 
be explained by an increase of plasma levels of active, free t-PA. Although 
the increase of t-PA has a transient character, the clinical effect may 
extend over a considerably longer period, since t-PA may bind to fibrin and 
become incorporated in newly fanned haemostatic clots, resulting in an early 
lysis and insufficient haemostatic function. 
Larger series are necessary to correlate plasma levels of t-PA with intra-
operative bloodless. 
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SUMMARY 
Primary cultures of human hepatocytes were analyzed for their ability to 
secrete the plasma hemostasis proteins protein C and plasminogen. Human 
hepatocytes were isolated from five left liver lobes by a two step perfusion 
technique with collagenase. Cells were cultured as a monolayer and culture 
medium was refreshed every 24 h. For quantification of human plasminogen 
we developed a specific enzyme immuno-assay (ELISA). Another specific 
ELISA was used for the determination of human protein C. Protein C and 
plasminogen concentrations in 24 hrs-culture medium increased for 5 days 
and rapidly declined thereafter. Addition of triiodothyronine resulted in a 
significant reduction of protein C (18 to 21%, p<0.02) and of plasminogen 
secretion (26 to 34%, p<O.Ol). Low doses of dexamethasone stimulated plas-
minogen secretion. Addition of insulin resulted in a significant reduction of 
protein C (20%, p<0.02) and plasminogen secretion (17%, p<0.05). It was 
demonstrated for the first time that normal human hepatocytes in primary 
culture secrete protein C and plasminogen. These data suggest that human 
hepatocytes m primary culture may be an interesting and useful model to 
investigate the molecular processes underlying regulation of biosynthesis and 
secretion of human coagulation proteins. 
INTRODUCTION 
Protein C is a 
and profibrinolytic 
!55 
vitamin K dependent protein which possesses anticoagulant 
activity upon activation by thrombin and the endothelial 
cofactor thrombomodulin (1,2). In clinical studies, low plasma levels of 
protein C were found in patients with severe liver disease (3,4). Recently, a 
child with a homozygous protein C deficiency had a complete restoration of 
protein C activity after orthotopic liver transplantation (5). These observa-
tions strongly suggest the liver as its site of synthesis. Although Wion et al. 
(6) have reported the detection of protein C antigen in perfused human 
whole liver and liver cells suspensions, contradictory results were obtained 
from studies using the established human liver cell line Hep G2. Fair and 
Marlar (7) reported the synthesis of protein C antigen by cultured Hep G2 
cells, but Morita et al. (8) were unable to detect protein C antigen in 
culture media of Hep G2 cells. 
Plasminogen is a plasma glycoprotein which can be converted into the 
serine protease, plasmin, upon proteolytic modification. Although the site of 
plasminogen synthesis has been controversial for a long time, it was 
recently demonstrated that plasminogen is mainly synthesized by the liver 
(9,10). Examination of genetic types of plasminogen from a donor and a 
recipient before and after orthotopic liver transplantation have demonstrated 
that the liver is the principal site of synthesis of human plasminogen (9). 
Furthermore, primary cultures of rat hepatocytes and human hepatocellular 
carcinoma cell lines were found to synthesize and secrete plasminogen (1 0-
12). 
Recently, it was demonstrated that normal human hepatocytes can be 
isolated from pieces of human liver tissue and that these cells retain their 
morfology and several specific liver cell functions, when maintained as 
monolayers in cell cultures (13,14). Although primary cultures of human 
hepatocytes have been found to synthesize and secrete some plasma proteins 
(14,15), thus far no studies have been reported on the production of 
hemostasis proteins. Since the amount of hemostasis proteins, secreted by 
liver cells m cultures is expected to be low, highly sensitive immune-
assays are necessary for quantification of the trace amounts of proteins in 
the culture medium. 
In this study we used two enzyme immuno-assays (ELISA) for the deter-
mination of human protein C and plasminogen, to examine whether these 
hemostasis proteins are secreted by primary cultures of human hepatocytes. 
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In addition, we investigated the effect on protein C and plasminogen 
secretion of some hormones that are generally used in cell culture and that 
may have stimulating effects on hepatocyte function and survival (15). 
MATERIALS AND METHODS 
Isolation of Human Hepatocytes 
Human hepatocytes were isolated from the left lobes of livers which 
were taken during human donor nephrectomy in one case, and from four 
livers that were obtained through the Auxiliary Partial Liver Transplantation 
Program carried out at the University Hospital Dijkzigt in Rotterdam, The 
Netherlands. Permission was given by the Medical Ethical Committee to use 
the remaining not transplanted part of the donor liver for scientific re-
search. The livers were taken from five physically healthy organ donors (4 
females and I male, aged from 6 to 42 years), who died after brain hemor-
rhages or severe traumatic brain injury and in one case carotid artery 
occlusion. During resection of the left lobe, the liver was perfused by portal 
vein cannulation with Euro-Collins (4°C). Isolation of human hepatocytes was 
essentially as described before (16, 17). After resection, the left liver lobe 
was transported to the perfusion site within 45 min in a cold buffer (4°C) 
containing 10 mM HEPES, pH 7.4, 142 mM NaCI, 16.7 mM KCI and 0.5 mM 
EGT A. Perfusion with 3 liter of this buffer at a rate of 40 ml/min per 
catheter was started after insertion of four polyethylene catheters (18 gauge) 
in the vascular orifices that could be identified at the dissection surface. 
After the pre-perfusion the liver was perfused successively with 500 ml of a 
HEPES buffer, pH 7.6, containing 5mM CaC12 without recirculation, and with 
200 ml of this buffer containing 0.05% and 0.1% collagenase, respectively, 
with recirculation for 20 min each. Liver tissue was dissociated in a Hanks 
buffer containing 2% bovine serum albumin, cells were filtered through a 250 
~m filter, centrifuged (75 x g for 5 min) and washed three times in a cold 
culture medium (4°C) to remove damaged and non-parenchymal cells. 
Viabilities were examined by trypan blue exclusion test, using 0.11% trypan 
blue. 
Human Hepatocyte Cultures 
The hepatocytes were seeded on 6-well cluster plates (35 mm diameter) 
(Costar, Cambridge, MA, U.S.A.) at a density of 1.25 x 105 cells!cm2 and 
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were maintained in Williams E medium (Flow Laboratories, Irvine, Scotland, 
UK) supplemented with 10% heat-inactivated fetal calf serum, 2 mM !-
glutamine, 100 U/ml penicillin, 100 )lg/ml streptomycin and 100 )lg/ml 
kanamycin (WE!10%FCS), and 135 nM insulin and 50 nM dexamethasone at 37 
°C in a 5% C02 I 95% air atmosphere. The medium (1 ml per 10 cm2) was 
renewed 10-16 h after seeding to remove unattached non viable cells and 
every 24 h thereafter. The cells were examined daily by light-microscopy. 
Following this procedure the percentage of parenchymal cells after attach-
ment of the cells and during 72 hours in culture was found to be 96% or 
more (18). At the indicated intervals medium was removed, centrifuged 
(10000 x g, 1 min) and the supernatants were collected and stored at -20 
0 C. After washing three times using cold Hanks' buffer ( 4°C), cells were 
harvested by scrapping the wells and stored at -20°C for total protein 
determination. 
Additional experiments were performed with cells cultured for 40 - 88 h, 
to assess the effect of hormones on the secretion of protein C and plas-
minogen. In these experiments hepatocytes were initially cultured in 
WE/10%FCS, supplemented with dexamethasone and insulin, for 16 h. During 
this period the cells were able to attach to the culture dishes and form 
monolayers. Culture medium was removed and replaced by hormone-free 
medium for the following 24 h. After 40 h, cells were refreshed with 
WE/l0%FCS to which one of the following hormones was added: dexa-
methasone (Dex) (in concentrations of 0.05 )lM; 0.2 )lM; 1 )lM or 10 )lM), 
triiodothyronine (T 3) (concentrations: 1 )lM or lO )lM), insulin (Ins; 135 nM), 
or a combination of lO )lM T 3 and 50 nM Dex. 
Determination of proteins 
Total protein was measured according to Lowry et al (19) with bovine 
serum albumin as standard. 
In order to quantify trace amounts of human protein C and plasminogen 
in the presence of an excess of fetal calf serum, we used a commercially 
available ELISA for protein C and we developed an ELISA for the specific 
quantification of human plasminogen. 
Enzyme immuno-assay for human protein C 
The ELISA for human protein C was based on two polyclonal anti-human 
antibodies (Boehringer Mannheim, Mannheim, FRG) (20). For quantification 
of the secreted amount of protein C antigen, culture medium was diluted 1:1 
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in the dilution buffer, supplied in the assay-kit. A calibration curve was 
made from pooled normal plasma diluted in a mixture of the same dilution 
buffer and Williams E medium (1:1). The amount of protein C antigen 
secreted in the culture media was expressed in U/mg cell protein/24 h (1 U 
== 1% normal plasma, containing approximately 30 ng/ml). 
Enzyme immuno-assay for human plasminogen 
The ELISA, we developed for quantification of human plasminogen, is 
based on the double antibody sandwich principle and can be performed on 
microtitre plates. 
Assay procedure. 
Microtitre plates (Niinc Immunoplate, Niinc, Roskilde, Denmark) were 
coated with 200 ).11 rabbit polyclonal anti-human plasminogen (lgG cone. 11.7 
g/1, Dakopatts Ltd, Glostrilp, Denmark) dissolved in a phosphate buffered 
saline (PBS) coating buffer (2.5 mM NaH2Po4.H20, 7.5 mM Na2HP04.2H20, 
145 mM NaC!, pH 7.2) and left covered with plastic film overnight at 4 °C. 
The plates were washed three times with a washing buffer [PBS buffer, pH 
7.2, with 0.1% (v/v) Tween 20 (Merck, Darmstadt, FRG) and 1 mM NarEDTA 
(Merck)]. Pooled citrated plasma, prediluted (1: 104 - 1: 16xl04) in a dilution 
buffer [PBS buffer, pH 7.2, with 0.1% (v/v) Tween 20, lmM Na2-EDTA and 
3% (w/v) PEG 6000 (Merck)] served as standard and for controls we used 
pooled EDTA-plasma, diluted 1:40,000 and 1:20,000 in the dilution buffer. Test 
samples were diluted with dilution buffer and 100 ).11 was added to each well. 
The plates were incubated at room temperature for 2 h and shaken con-
tinuously. After washing, 100 ).11 specific peroxidase-conjugated rabbit anti-
human plasminogen antibody (lgG cone. 1.3 g/1, Dakopatts Ltd) diluted 1:2000 
in dilution buffer was added to each well and incubated at room temperature 
for 1 h under continuous shaking. After washing, enzyme color reaction was 
started by adding 100 ).1! of freshly prepared color reagent, orthophenyl-
ediamine (0.67mg/ml) in citric acid phosphate buffer (34.7 mM citric acid, pH 
5.0 containing 66.7 mM Na2HP04) to each well. After incubation for 15 min 
at room temperature, the reaction was stopped by adding 150 ~I 1M H2so4 
to each well. The absorbance was measured after 15 min at 492 nm with a 
Titertek Twinreader (Flow Laboratories, Virginia, USA). The standard curve 
was plotted on log-log paper with log A 492 nm as ordinate and log concen-
tration of standards as abscissa. Concentration of the test samples were read 
by means of interpolation of this standard curve. 
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Statistical analysis 
Statistical analysis was performed using Wilcoxon's signed rank test. 
Differences were assumed to be statistically significant when p-values were 
less than 0.05. 
RESULTS 
Isolation and culture of human hepatocytes 
Hepatocytes were isolated from 5 left liver lobes. Cell yield varied from 537 
to 1670 x106 hepatocytes with a viability of 70% - 81% (table 1). In culture, 
the initially spherical hepatocytes attached themselves to the culture plastic 
within 6 h, aggregated and fanned monolayers of cells with a characteristic 
polygonal shape during the first 40 h. During the first 5-6 days, hepatocytes 
were morfologically in a stable condition and resembled cells in vivo (figure 
1). 
Table 1. Cell yield and viability of five human hepatocyte isolations 
Isolation Cell Yield Viability (%) 
537 x 106 71 
2 1280 X 106 70 
3 1290 X 106 81 
4 115lx106 77 
5 1670x 106 73 
Fig 1. 
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Phase contrast micrograph of human hepatocytes cultured for 72 h 
in primary monolayers (original magnification x 100). 
Secretion of protein C by human hepatocytes 
The ELISA used for protein C was found to be highly specific for human 
protein C and did not cross-react with the FCS, as no protein C antigen 
was detected in control experiments with unconditioned Williams E medium, 
supplemented with 10% FCS. In experiments from two separate cell isola-
tions, concentrations of protein C in the culture medium was measured 
during a period of lO days. After 4-5 days, protein C concentration in 
culture medium reached a maximum of about 0.5% of the concentration in 
normal plasma and rapidly declined thereafter (figure 2). 
Fig2. 
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Time course of protein C secretion by primary cultures of human 
hepatocytes, obtained after isolation from the left lobes of two 
different livers. Cells were cultured in Williams E medium, supple-
mented with 135 nM insulin and 50 nM dexamethasone. The values 
are expressed in units per milliliter of medium per day (1 U = 1% 
normal plasma). 
Determination of human plasminogen and secretion by human hepatocytes 
Human Plasminogen ELISA. 
The standard curve of plasminogen 
Using the ELISA it was possible 
from about 6.25xlo-4 to lxl0-2% of 
ELISA procedure is shown in figure 3. 
to quantify plasminogen concentrations 
normal pool plasma (cone. 1.5 ~mol/1). 
The intra-assay 
within the ranges 
coefficient of variation for plasma 
of about 40 pM to 80 pM was 5.3% 
plasminogen 
(n=40), and 
measured 
the inter-
assay variation (n=21) over the same range was 15%. The specificity of the 
assay was checked by determination of the recovery of purified plasminogen 
(more than 98%), and the negligible interference of other plasma proteins. 
This included apoprotein (a), which is a lipoprotein (a)-specific antigen that 
is structurally closely related to plasminogen (21). 
Fig 3. 
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Plasminogen in cell cultures. 
When unconditioned Williams E medium, supplemented with 10% FCS was 
analyzed with the plasminogen ELISA, very low absorbances were measured, 
indicating some cross-reactivity with FCS. Therefore all results were 
corrected, using WE/10%FCS as the blank. In experiments from two separate 
cell isolations, plasminogen secretion was measured during a culture period of 
10 days. Concentration of plasminogen in culture medium increased for 5 
days, reaching a maximum value of about 0.5% of its plasma concentration, 
and rapidly declined thereafter (figure 4). 
Fig4. 
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Time course of plasminogen secretion by primary cultures of human 
hepatocytes, obtained after isolation from the left lobes of two 
different livers. Cells were cultured in Williams E medium, supple-
mented with 135 nM insulin and 50 nM dexamethasone. The values 
are expressed in nmoles per milliliter of medium per day. 
Effect of hormones on secretion of protein C and plasminogen by human 
hepatocytes 
Hormonal incubations were performed during a time interval of 40-88 h, 
using hepatocytes obtained from three different cell isolations. The secretion 
of protein C and plasminogen, in control experiments with hormone-free 
medium, during this period is shown in table 2. The amount of secreted 
protein varied somewhat between the experiments, using cells from different 
livers. The effect of the hormonal incubations on the secretion of protein C 
and plasminogen, expressed in percentage of the corresponding control 
experiments is shown in table 3. Addition of 0.05 and 0.2 ~M Dex to the 
culture medium resulted in an increase of plasminogen secretion by 28% 
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(p<0.02) and 25% (p<0.05), respectively, but no significant effect on protein C 
secretion was found. Higher amounts of Dex did not have any significant 
effect on plasminogen secretion. After incubating the cells with 1 ~M or 10 
~M T 3, a significant reduction of both protein C and plasminogen secretion 
was seen (table 3). If 0.05 ~M Dex and 10 ~M T3 were added to the culture 
medium simultaneously, protein C and plasminogen secretion were not signifi-
cantly different from the control experiments. When the cells were grown in 
medium with 0.135 ~M insulin, protein C and plasminogen secretion decreased 
by 20% (p<0.02) and 17% (p<0.01), respectively. 
Table 2. 
Experiment 
Control 1 
Control2 
Control 3 
Secretion of protein C antigen and plasminogen antigen by 
human hepatocytes in hormone-free medium, cultured for 40-88h 
Protein C 
(U/mg cell protein/24 h) 
1.32±0.44 
1.99±0.17 
1.04±0.12 
Plasminogen 
(nmoVmg cell protein/24h) 
4.33±0.29 
2.56±0.20 
Results are means ± SEM of 6-8 fold cultures, with duplicate determinations 
of protein C and plasminogen antigen. *NA = not assayed. 
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Table 3. The effect of hormonal incubations on protein c and plas-
minogen secretion in human hepatocytes, cultured for 40-88h 
Effect on Effect on 
Protein C Plasminogen 
Hormone treatment % of cohtrolsa % of controls3 
Dexamethasone (Dex) 
0.05 ~M 8% NSb +28% p<0.02 
0.2 ~M + 2% NS +25% p<0.05 
I ~M + 8% NS + 10% NS 
10 ~M + 9% NS + 10% NS 
Triiodothyronine (T 3) 
I ~M 22% p<0.02 26% p<O.Ol 
!O~M 18% p<0.02 34% p<O.O! 
10 ~M T3 + 0.05 ~MDex 9% NS 2% NS 
0.135 ~M Insulin 20% p<0.02 17% p<0.05 
Results are means of 2-3 isolations with 2-4 fold incubations and duplicate 
determinatio~ of protein C and plasminogen. 
•see table 2, NS =not significant . 
DISCUSSION 
Almost all proteins of the hemostasis system have been found to be 
synthesized by the liver (22). Indications for the synthesis of hemostasis 
proteins by the liver were partly based on clinical data, documenting 
reduced plasma levels of the proteins in patients with severe liver disease. 
Furthermore, the human hepatoma cell line, Hep 0 2, was found to have the 
capacity to synthesize several components of the hemostatic system 
(11,12,23). This cell line has been used to study intracellular processes and 
regulation of synthesis of some of these proteins (24). However, cell lines 
originating from liver tumors may physiologically not be fully comparable 
with normal human liver cells. Theoretically, cultures of normal human 
hepatocytes represent the ideal in vitro model for studies of specific liver 
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cell functions in a well-defined environment (15). Recently, it was demon-
strated that human hepatocytes can 
normal liver tissue by means of 
be isolated successfully from pieces of 
a perfusion technique with collagenase 
(13,14). Isolated hepatocytes could be maintained in cell culture for several 
days, during which they demonstrated several specific liver cell functions 
(15). Although human hepatocytes in primary culture were found to produce 
albumin (14,25) and some other plasma proteins (15), reports on the produc-
tion of hemostasis proteins are limited to a study on plasminogen activator 
inhibitor (16). Primary cultures of human hepatocytes may be a physiologi-
cally good model to investigate synthesis 
of normal liver tissues for scientific 
of these proteins. However, the use 
research is limited, especially for 
ethical reasons. A rather unique situation resulted from the auxiliary 
is transplanted 
liver 
transplantation, in which only a part of 
The resected part (usually the left lobe) 
is very suitable for isolation of liver cells. 
the donor liver (26). 
is not used for transplantation and 
In this study we used lobes from 5 livers for cell isolation. The cell 
yield was rather constant with a good viability of the cells. The ELISA used 
to detect protein C was found to be highly specific for human protein C as 
no cross-reactivity occurred with unconditioned Williams E medium containing 
10% FCS in control experiments. Therefore, hepatocytes could be maintained 
on medium supplemented with FCS throughout the experiment, which is found 
to be of importance for long term culture of human hepatocytes (27,28). For 
quantification of plasminogen in the culture medium we developed a specific 
ELISA for human plasminogen. The range for plasminogen detected by this 
assay, was sufficiently broad to measure accurately plasminogen in culture 
medium. Secretion of protein C and plasminogen by human hepatocytes was 
found to increase for 4-5 days and rapidly declined thereafter. Other 
investigators have found a comparable pattern for the secretion of albumin 
by human hepatocytes in primary culture (14,25). 
Experiments with hormonal incubations were performed between 40 and 88 
h. In this period the cells were morfologically in a stable and good condition 
and had an optimal secretion of protein C and plasminogen. It is known that 
hormones either alone or in a mixture may strongly influence synthesis of 
certain plasma proteins (15). We examined the effect on protein C and 
plasminogen secretion of three hormones that are generally used in cell 
culture and that may have a stimulating effect on the hepatocytes. In none 
of the used concentrations an effect of Dex was found on protein C secre-
tion, but plasminogen secretion was stimulated in the presence of low 
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amounts of Dex. A similar stimulating effect has been observed for other 
proteins (29,30), and this may result from the beneficial effect of this 
hormone on cell metabolism and various functions in hepatocyte cultures 
(15). Lack of effect on protein c secretion may be explained from differen-
ces in the in vivo synthesis rate of the two proteins. From the plasma half 
lives and plasma concentrations it can be calculated that in vivo plasminogen 
synthesis is about twice the synthesis of protein C. An in vitro stimulating 
influence of Dex may have a greater effect on the protein with the highest 
rate of synthesis, which is plasminogen in this case. Noteworthy was the 
lack of effect by higher amounts of Dex, which suggests a dose dependent 
mechanism. Triiodothyronine seemed to decrease the secretion of both 
protein C and plasminogen. This is probably due to a non specific effect on 
cell metabolism, since T 3 at concentrations used in this study may cause a 
depletion of the ATP cell content (31). Another explanation may be that 
general protein turnover and breakdown is stimulated by T3, as was recently 
found in cultured rat hepatocytes (32). When cells were grown in the 
presence of both Dex and T 3 the effect of both hormones seemed to 
counteract each other, resulting in a protein C and 
not different from control experiments. Maekudo et 
plasminogen secretion 
a!. (33) found that 
human hepatocytes in primary culture retain the ability to bind and respond 
to insulin. Although insulin stimulates albumin synthesis in rat hepatocytes 
(34,35), we observed a slightly negative effect of insulin on both protein C 
and plasminogen secretion, for which we do not have a good explanation. 
In conclusion we found for the first time that human hepatocytes in 
primary culture secrete protein C and plasminogen into their medium. 
Furthermore, it seems that human hepatocytes in primary culture maintain 
reactivity to some hormones, probably indicating that receptors at the cell 
membrane are preserved during the isolation procedure. Thus, human 
hepatocytes in primary culture seem to provide an interesting and useful 
model to investigate the molecular events underlying the regulation of 
biosynthesis and secretion of human coagulation proteins. 
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GENERAL DISCUSSION AND CONCLUSIONS 
9.1 Rationale of the study 
Orthotopic liver transplantation (OLT) is now generally accepted as a 
realistic treatment for patients with end-stage liver disease1•2. However, the 
surgical procedure is technically demanding and sometimes the poor clinical 
condition of patients is considered to be too a high a risk for a successful 
OLT. In some centers OLT is currently not considered m patients with 
fulminant hepatic failure. For these patients auxiliary partial liver transplan-
tation may be a reasonable alternative. 
In spite of the improved results of OLT, the surgical procedure is still 
associated with large amounts of blood loss3A, which is correlated with an 
increased peri operative mortality 4•5. Part of this blood loss is related to the 
magnitude of the surgical trauma6. However, a poor preoperative hemostatic 
function and specific intraoperative deteriorations of the hemostatic system 
may contribute 7 ,& . Although there are theoretical grounds to assume that 
blood loss and the deteriorating effect on hemostasis will be less severe in 
APL T, there is 
v1ew. A large 
no objective clinical or experimental evidence to sustain this 
number of papers have been published on the hemostatic 
disorders in liver transplantation, but the mechanisms that are responsible 
for the hemorrhagic diathesis in liver transplantation are still poorly under-
stood. The role of the fibrinolytic system has been subject of many specula-
tions. An increased fibrinolytic activity is found in may patients undergoing 
OLT9-ll, but the underlying mechanisms of this activation and its clinical 
relevance are not clear. Interpretation and comparison of the results of 
different groups is difficult due to differences in surgical and anesthesiologic 
techniques and in laboratory methods. Interpretation of hemostasis tests has 
also often been difficult, and many of the assay methods used in the earlier 
studies are now known to be nonspecific or insensitive. During the past 
decade, knowledge about the hemostatic system has increased greatly. Many 
new proteins and activating or inhibiting pathways of the hemostatic system 
have been recentely discovered (for reviews see 12). The introduction of 
specific chromogenic substrate methods and sensitive enzyme immune-assays 
have provided tools to study these new aspects of the hemostatic system. 
Some of these new assays have been used in the studies described in 
this thesis. The aim of the investigations was to study the effect of APLT 
on the hemostatic system and the mechanisms that cause some specific 
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hemostatic changes during both OLT and APLT. We also evaluated the 
possibility of using resected parts of human donor livers used for APL T for 
in vitro studies. From this human liver tissue, hepatocytes were isolated and 
maintained in primary culture to study the secretion of plasma hemostasis 
proteins. 
9.2 Hemostasis in orthotopic liver transplantation 
An 
function 
tion7•8 
function 
important problem in OLT is the 
which is found m many patients 
This sometimes warrants attempts 
by the substitution of blood and 
poor preoperative hemostatic 
with severe hepatic dysfunc-
to improve the hemostatic 
blood-products preoperatively or 
during the first part of the 
centers now tend to select 
stage of their liver disease, 
pathy. 
surgical procedure. Partly for this reason some 
patients for liver transplantation at an earlier 
when they have less severe secondary coagula-
Specific changes occur in the hemostatic mechanism intraoperatively. 
These changes may further 
necessitate the transfusion 
complicate bleeding of traumatic origin, and may 
of large amounts of blood. The observed intra-
operative deterioration of hemostasis has been 
disseminated intravascular coagulation (DIC)I3-lS, 
combination of both processesl8,l9 Although DIC 
interpreted as a sign of 
hyperfibrinolysis16•17 or a 
may have played a role m 
the earlier experiments and clinical studies, some investigators dispute its 
clinical relevance and its role in the increased bleeding tendency during 
OLT16•20 The occurrence of DIC is largely dependent on the quality of the 
donor live~1.22. Improvements in graft preservation techniques, surgical and 
anesthetic procedures and a more stringent substitution therapy have 
undoubtedly contributed to the decreased occurrence of hemostatic changes 
suggestive of DIC. The concept that DIC does not play a clinicalJy important 
role in OLT is supported by the failure to find evidence for thrombo-embolic 
processes in histological or clinical examination23-25. Using electron micros-
copy, performed on liver biopsies taken 5-10 min after graft reperfusion, we 
were also unable to find microthrombi or signs of platelet aggregation 
(chapter 4). Some authors, however, have described an intraoperative 
decrease of clotting factors and inhibitors like antithrombin III in their 
patients undergoing OLT and interpreted these as signs of mcl8,l6_ How-
ever, we have also seen a decrease of antithrombin III and fibrinogen levels 
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undergoing in heparinized patients 
strongly suggests that 
may play a role in 
other, less 
the changes in 
major vascular surgery (chapter 5). This 
specific processes, such as hemodilution, 
coagulation during liver transplantation as 
well. 
Despite all 
during recent 
in a majority 
the improvements in surgical and anesthetic management 
years, intraoperative signs of hyperfibrinolysis are still found 
of the OLT patientsl0,ll,20 Although the origin of this 
increased fibrinolytic activity is still controversial, there is growing evidence 
for a primary mechanism. By comparing fibrinolytic activities, as measured by 
the euglobulin clot lysis time, during both OLT and APLT we observed a 
more sustained increase in fibrinolytic activity during OLT (chapter 3). We 
also found that reperfusion of the donor liver is associated with an increase 
of fibrinolytic activity. In blood samples taken from the first hepatic 
outflow, fibrinolytic activity was significantly increased compared with the 
systemic circulation (chapter 4). In a study in 20 OLTs we found an increase 
of tissue-type plasminogen activator (t-PA) activity during the anhepatic 
stage, followed by an "explosive" 30-fold increase immediately after graft 
reperfusion (chapter 6). Recently, Dzik et a1. 11 have reported a similar 
increase of t-PA during the anhepatic stage in a limited number of patients 
undergoing OLT. However, this study did not show the explosive t-PA 
increase, occurring directly after graft reperfusion, as seen 
Since we observed a rapid return to normal of t-PA 
maximum levels, this peak could easily 
within 10 minutes 
have been missed 
in our patients. 
activity after the 
if blood samples 
were not taken both studies, 
however, patients with high levels of 
after 
t-PA 
reperfusion. In 
suffered from extensive intra-
operative blood loss. 
degradation products 
levels. We found 
We also found significantly 
of fibrinogen and fibrin in 
a similar steady increase of 
higher plasma levels of 
patients with high t-PA 
thrombin-antithrombin III 
complexes in patients with severe and minimal fibrinolysis, indicating that 
increased t-PA activity was not related to thrombin formation (chapter 6). 
The intraoperative course of t-PA activity in patients undergoing OLT, 
m combination with the results of the experimental studies (chapter 4), 
strongly suggest that hyperfibrinolysis during OLT is caused by two different 
mechanisms. In the first place hyperfibrinolysis may occur during the 
anhepatic stage due to a combination of an increased endothelial release of 
t-PA and a reduced hepatic clearance. Secondly, reperfusion of the donor 
liver may have a stimulatory effect on the fibrinolytic system. Our findings 
suggest that release of t-PA from the intrahepatic endothelium may cause a 
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temporary increase in fibrinolytic activity 
of the 
after graft reperfusion. This 
process might depend on the quality graft and the magnitude of the 
ischemic damage. Since the primary increase in t-PA activity was associated 
with an active proteolytic destruction of fibrinogen and fibrin and a high 
blood loss, the use of antifibrinolytic drugs may be justified in patients with 
life threatening hemorrhages when there is evidence for active fibrinolysis. 
To identify these patients, it is advisable to include at least one test method 
for the assessment of fibrinolytic activity in the intraoperative hemostasis 
monitoring in orthotopic liver transplantation. 
Another phenomenon that is often encountered in patients undergoing 
OLT and that may play a role in the hemorrhagic diathesis, is a decrease in 
platelet count23,l?. Despite transfusion of platelet concentrates, severe 
thrombocytopenia may occur 
blood samples taken from the 
we found significantly lower 
circulation (chapter 4), This 
during 
venous 
platelet 
is in 
the first 
outflow 
counts, 
agreement 
postoperative days27,28 In 
of the reperfused liver graft, 
compared with the systemic 
with the findings of other 
investigators and strongly suggests sequestration of blood platelet m the 
liver graft25,l9_ Since we could not find any histologic evidence for intra-
vascular coagulation or platelet aggregation in the livers, other processes 
than DIC are probably responsible for this phenomenon. In electron micros-
copy studies we found signs of a phagocytosis of platelets by Kupffer cells 
while other platelets were lying free in the sinusoids (chapter 4), It is of 
interest that we could not confirm the earlier observations of Hutchison et 
al. 23, who described an extravasation of platelets into the space of Disse. 
In general, it seems that bleeding problems in OLT are largely dependent 
on the preoperative condition and hemostatic 
OLT, Intraoperatively, primary hyperfibrinolysis 
in the further deterioration of the hemostatic 
status of 
may play 
function. 
patients undergoing 
an important role 
Rapid restoration of 
the hemostatic balance after recirculation seems to be largely dependent of 
the quality of the liver graft 
9.3 Hemostasis in auxiliary partial liver transplantation 
Auxiliary partial liver transplantation (APLT) is theoretically an attractive 
alternative to OLT. The traumatizing and blood consuming surgical removal 
of the host liver can be avoided and there is no period m which the hepatic 
function is completely absent30,31 APLT might have less disturbing effects 
on the 
reduced 
hemostatic system and the 
need of blood transfusion. 
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procedure 
In patients 
might provide temporarily life support during 
might be associated with a 
with acute hepatic failure it 
a period in which the own 
liver has a change to recover to normal functional capacity. 
We indeed found less blood loss during APLT, compared with OLT, in a 
controlled study in healthy pigs (chapter 3). The main difference between 
the effects of APL T and OLT on hemostasis was a less sustained increase in 
fibrinolytic activity during APLT (chapter 3). This supports the theory that 
increased hyperfibrinolysis in OLT is at least partly due to reduced hepatic 
clearance of plasminogen activators during the anhepatic stage. After 
recirculation, we found a similar decrease in platelet count and an increase 
in fibrinolytic activity in the venous outflow of auxiliary and orthotopic liver 
allografts. Remnant clearing function of the native liver might have contri-
buted to a rapid normalization of fibrinolytic activity in the systemic 
circulation during APLT. Although signs of hyperfibrinolysis have been 
reported in about 80% of the patients undergoing OLT16, we have seen a 
period of increased fibrinolytic activity in only 2 of the 8 patients under-
going APLT (chapter 7). The signs of hyperfibrinolysis, as measured by 
thrombelastography, were found before graft recirculation in one patient and 
after recirculation in another. Both patients had high levels of t-PA activity 
and suffered from increased intraoperative blood loss, which gives further 
support for the role of t-PA in hyperfibrinolysis and uncontrollable bleeding 
in liver transplantation. 
Based on the present studies 
disturbing effect on hemostasis 
it seems that APLT has, in general, a less 
than OL T. Larger series of patients are 
necessary to evaluate whether APLT is indeed associated with a lower 
bleeding risk and whether it is a realistic alternative for patients at high 
risk for OLT. 
In the currently used technique for auxiliary liver transplantation, only a 
part of the liver is grafted3l,32. Since the resected part is not used for 
transplantation, this provides interesting material for scientific research. In 
the last study presented in this thesis, the resected parts of the donor livers 
used for APLT were used for liver cell isolation (chapter 8). It was demon-
strated that the isolated hepatocytes can be kept in primary culture and are 
capable of secreting some plasma hemostasis proteins. This in vitro model 
seems to be an interesting method to study the regulation of the biosyn-
thesis of hemostasis proteins by "nonnal" human hepatocytes. The unique 
179 
situation in which one part of a liver is used for transplantation, whereas 
the other part can be used for scientific research might also provide an 
interesting model to study other aspects of liver transplantation, such as 
graft preservation damage, primary non-function and hepatic regeneration. 
More studies are necessary to explore the scientific possibilities provided by 
this combination of clinical liver transplantation and in vitro experiments. 
9.4 Conclusions 
1. By comparing orthotopic and auxiliary partial liver transplantation it was 
demonstrated that, in healthy animals, APLT may be associated with a 
50% reduction in intraoperative blood loss and a less pronounced activa-
tion of the fibrinolytic system. These findings support the theoretically 
different effects of both types of liver transplantation on hemostasis. 
2. We showed that the donor liver may play a role in the origin of 
thrombocytopenia and hyperfibrinolysis during liver transplantation. Graft 
reperfusion was associated with a sequestration of blood platelet in the 
sinusoids and phagocytosis by Kupffer cells of the donor liver. Blood 
samples taken directly from the hepatic vein showed an activation of the 
fibrinolytic system. 
3. Using a compact coagulation analyzer, heparin levels and some hemo-
static parameters could be measured in the operation room at 20 min 
intervals. Rapid determination of heparin levels provided new insights in 
the heparin concentrations and the elimination of heparin during major 
vascular surgery. 
4. In 20 OLTs the occurrence and systemic effects of hyperfibrinolysis were 
studied. An 30-fold increase of tissue-type plasminogen activator (t-PA) 
activity was seen immediately after graft reperfusion in 13 of the 20 
patients. High levels of t-PA activity were associated with the destruction 
of fibrinogen and fibrin, which is consistent with the clinical signs of 
severe oozing often seen in this period of the operation. 
5. In the first patient which underwent APLT, coagulation and fibrinolytic 
parameters were studied extensively. It was concluded that in a severely 
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diseased patient with an end-stage of liver cirrhosis, APLT may be 
performed without serious changes in the hemostatic system and without 
serious intraoperative blood loss. Synthetic function of the auxiliary liver 
was reflected in the normalization of hemostasis parameters during the 
first postoperative days. 
6. The fibrinolytic system was studied during and after eight consecutive 
cases of APLT m man. Intraoperative signs of fibrinolytic activation 
were found in only two of the eight cases and they were associated with 
increased levels of t-PA activity in the circulation. Postoperatively, 
persistent high levels of plasminogen activator inhibitor activity were 
found in patients with a primary non-functioning liver graft. 
7. An in vitro model was developed to study the regulation of synthesis of 
hemostasis proteins by human hepatocytes. Human hepatocytes were 
successfully isolated from the resected parts of donor livers, used for 
APLT. Maintained in primary cell culture, the cells were able to secrete 
protein C and plasminogen. There was evidence for some reactivity of the 
cells to triiodothyronine, dexamethasone and insulin. 
We think that the results of these experiments have provided more 
insight m the mechanisms underlying the hemostatic disorders in OLT and 
APLT. Larger series of patients are necessary to study the exact role of 
specific hemostatic disorders in the occurrence of severe intraoperative 
bleeding. This may further increase our understanding of the origin of the 
hemorrhagic diathesis in liver transplantation. Hopefully, this will provide the 
basis for improvements in therapeutical management and will lead to a 
further reduction of the usage of blood products in liver transplantation. 
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SUMMARY 
In this thesis clinical and experimental studies on hemostatic disorders in 
orthotopic (OL T) and auxiliary partial 
described. The studies were designed to 
the hemostasis system and to study the 
regarding intraoperative blood loss and 
the underlying mechanism of specific 
liver transplantation (APLT) are 
investigate the effect of APLT on 
differences between OLT and APLT, 
changes in hemostasis. In addition, 
hemostatic disorders, which occur 
during both types of liver transplantation was studied. 
In the introduction to this thesis in chapter 1, general information on the 
evolution of OLT and the development of an improved surgical technique 
for APLT is given. The theoretical differences between those two types of 
liver transplantation, regarding the effect on hemostasis is also briefly 
discussed. A review of the literature on hemostasis in liver transplantation is 
given in chapter 2. Based on this review, the working hypothesis for our 
own experimental and clinical studies were formulated. The results of these 
studies are reported in chapter 3, 4, 5, 6, 7, 8 and 9. 
In the first study, described in chapter 3, the effects of OLT and APLT 
on the hemostasis mechanism were compared in an controlled study in pigs. 
Intraoperative blood loss in APLT was about half the blood loss in OLT. 
There were no differences in the coagulation parameters during OLT and 
APLT. However, in OLT there was an increase in fibrinolytic activity during 
the anhepatic stage, and after graft recirculation a longer period of in-
creased fibrinolytic activity was observed, compared with APLT. Differences 
in surgical trauma and lack of an anhepatic stage in APLT may explain these 
observations. In the study described in chapter 4, the effect of graft 
reperfusion on the hemostatic mechanism and the role of the donor liver in 
the origin of hemostatic disorders was studied in more detail. This study was 
performed in pigs that underwent either OLT or APLT. A significantly lower 
platelet count and increased fibrinolytic activity were found in venous blood 
from the graft, compared with blood from the systemic circulation. Electron 
microscopy performed on liver biopsies did not show evidence for intravas-
cular coagulation or platelet aggregation. However, there were signs of 
phagocytosis of platelets by Kupffer cells of the graft. Although most 
platelets were lying free in the sinusoids, some of them had an agranulair 
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appearance. Since there was no evidence found for intravascular coagulation, 
either by hemostasis tests or histopathologic examination, the increased 
fibrinolytic activity after graft reperfusion was due to primary activation. 
In chapter 5, a laboratory system for the monitoring of hemostasis and 
heparin levels during major vascular surgery was tested. It was possible to 
perform a general hemostasis study, including heparin concentration, in a 
short period of time during major vascular surgery. It was demonstrated 
that the kinetic and elimination rate of heparin have a wide individual 
variation, which may lead to subtherapeutic heparin levels in some patients. 
In chapter 6 the origin and systemic effects of hyperfibrinolysis in OLT 
were studied. Hyperfibrinolysis, as measured by the euglobulin clot lysis time 
and thrombelastography, was associated with an high increase of tissue-type 
plasminogen activator (t-PA) activity and plasma fibrinogen and fibrin 
degradation products. Highest t-PA activity was found immediately after 
graft reperfusion, which is consistent with the clinical signs of severe oozing 
at this stage of the operation. 
The results of studies on hemostatic changes in APLT in man are 
described in chapter 7 and 8. In agreement with the animal studies (chapter 
3), it was found that APLT in patients with severe liver disease, may be 
associated with only minor changes in hemostasis. Especially signs of 
hyperfibrinolysis may occur less frequently and the increase m fibrinolytic 
activity may be less severe, compared with OLT. Increased fibrinolytic 
activity, as measured by thrombelastography, was found in only 2 of 8 
consecutive cases of APLT. In these two patients it was demonstrated that 
the increased fibrinolytic activity was caused by an enhanced t-PA activity. 
In chapter 9, the isolation and culturing of human hepatocytes, as an 
model for studying the regulation of the synthesis of hemostasis proteins by 
human hepatocytes is described. In these experiments liver tissue from 
donor livers that were used for APLT, was used. It was found that human 
hepatocytes 
proteins (i.e. 
the resected 
in primary cultures are capable to secrete plasmatic hemostasis 
situation 
research. 
protein 
part of 
C and plasminogen) 
a donor liver for in 
m which one liver is used both 
into their culture medium. Using 
vitro studies provides 
for transplantation and 
a unique 
scientific 
Furthyr clinical studies in both orthotopic and auxiliary partial liver 
transplantation are necessary to evaluate the role of the described hemo-
static deteriorations in the origin of severe intraoperative bleeding. 
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SAMENVATTING 
In dit proefschrift worden klinische en experimentele studies naar 
hemostase-afwijkingen in orthotope (OLT) en auxiliaire paniele lever-
om het effect transplantaties (APL T) beschreven. De studies waren opgezet 
van APLT op het hemostase-systeem te bestuderen en om de verschillen 
tussen OLT en APLT ten aanzien van intraoperatief bloedverlies en verande-
ringen in de hemostase te onderzoeken. Tevens werden de onderliggende 
mechanismen van specifieke hemostase-afwijkingen, welke voorkomen tijdens 
beide typen van levertransplantatie, bestudeerd. 
Algemene informatie over de evolutie van OLT en de ontwikkeling van 
een verbeterde chirurgische techniek voor APLT wordt gegeven in de 
inleiding van dit proefschrift in hoofdstuk 1. In het kort wordt ook ingegaan 
op de theoretische verschillen tussen deze twee typen levertransplantatie, ten 
aanzien van bet effect op de hemostase. Een overzicht van de literatuur over 
de hemostase bij levertransplantaties wordt gegeven in hoofdstuk 2. Aan de 
hand van dit overzicbt werden de werkbypotbeses voor onze eigen experi-
mentele en klinische studies geformuleerd. De resulaten van deze studies 
worden vermeld in de hoofdstukkken 3, 4, 5, 6, 7, 8 en 9. In het eerste 
onderzoek, beschreven in hoofdstuk 3, worden de effecten van OLT en APLT 
op het hemostasemechanisme vergeleken, in een gecontroleerde studie bij 
varkens. Het intraoperatief bloedverlies tijdens APLT was ongeveer de belft 
van dat tijdens OLT. Er waren geen verschillen in de stollingsparameters 
tijdens OLT en APLT. Tijdens OLT was er ecbter een toename m de 
fibrinolytiscbe activiteit in de anhepatische fase, en na recirculatie van bet 
transplantaat werd een verboogde fibrinolytische activiteit waargenomen 
bij APLT. Deze bevindingen kunnen 
in het chirurgisch trauma en het ontbre-
gedurende 
verklaard 
ken van 
een 
worden 
een 
langere periode dan 
door verschillen 
in APLT. In bet onderzoek beschreven m 
hoofdstuk 4 
anhepatiscbe fase 
wordt bet effect van reperfusie van het transplantaat op 
in bet ontstaan 
het 
hemostasemechanisme, en de rol van de donorlever van 
hemostase afwijkingen meer in detail bestudeerd. Dit onderzoek werd 
uitgevoerd bij varkens die een OLT of een APLT ondergingen. Veneus bloed 
rechtstreeks afkomstig uit het transplantaat vertoonde een significant lager 
aantal bloedplaatjes en een verhoogde fibrinolytische activiteit, vergeleken 
met bloed in de systernische 
van leverbiopten, toonde geen 
bloedplaatjesaggregatie. Er waren 
plaatjes door de Kupfferce!len 
187 
circulatie. Electronenmicroscopisch onderzoek 
aanwijzingen voor intravasale stalling of 
wei tekenen van phagocytose van bleed-
van het transplantaat. Hoewel de meeste 
bloedplaatjes vrij m de sinusoiden lagen, vertoonden sommige een agranulair 
aspect. Daar zowel hemostasetesten als histologisch onderzoek geen aanwij-
zingen gaven voor intravasale stalling, was er sprake van een primaire 
activatie van de fibrinolyse na reperfusie van het transplantaat. 
Hoofdstuk 5 beschrijft een laboratorium-systeem dat werd getest voor de 
monitoring van de hemostase en heparineconcentraties. Het bleek rnogelijk 
om tijdens grate vaatoperaties een algemeen hemostase-onderzoek, inclusief 
heparine bepaling, uit te voeren in een kort tijdsbestek. Tevens werd 
aangetoond dat de kinetiek en verdwijningssnelheid van heparine een brede 
individuele variatie vertonen, die kunnnen leiden tot subtherapeutische 
heparinespiegels in sornmige patienten. 
In hoofdstuk 6 worden de oorzaak en de systernische effecten van hyper-
fibrinolyse tijdens OLT bestudeerd. Hyperfibrinolyse, gemeten met de 
euglobulinestolsel-lysistijd en thrornbelastografie, bleek geassocieerd met een 
sterke toename van de weefsel-type plasminogeen activator (t-PA) en plasma 
fibrinogeen- en fibrine-afbraakprodukten. De hoogste t-PA activiteit werd 
gevonden direct na reperfusie van het transplantaat, wat in overeenstemming 
is met de klinische tekenen van ernstig diffuus bloedverlies ("oozing") 
gedurende deze periode van de operatie. 
In de hoofdstukken 7 en 8 werden de resultaten beschreven van onder-
zoeken naar hernostaseveranderingen tijdens APLT bij de mens. In over-
eenstemming met de dierexperimenten (hoofdstuk 3), bleek dat APLT bij 
patienten met ernstige leverziekten gepaard kan gaan met slechts minimale 
veranderingen in de hemostase. Met name komen tekenen van hyperfibrino-
lyse minder frequent voor en de toenarne in fibrinolytische activiteit kan 
minder ernstig zijn, vergeleken met OLT. Tijdens slechts 2 van de 8 APLTs 
werd met behulp van thrombelastography een verhoogde fibrinolytische 
activiteit gemeten. Bij deze twee patienten werd aangetoond dat de ver-
hoogde fibrinolytische activiteit veroorzaakt 
activiteit van t-PA. Synthesefunctie van het 
door de nonnalisatie van hernostaseparameters 
de operatie. 
wordt door 
transplantaat 
gedurende de 
een toegenomen 
werd aangetoond 
eerste dagen na 
In hoofdstuk 9 wordt de isolatie en het kweken van humane hepatocyten, 
als model voor de bestudering van de regulatie van de synthese van hemo-
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stase-eiwitten door humane hepatocyten, beschreven. In deze experimenten 
werd gebruik gemaakt van leverweefsel afkomstig van de donorlevers, welke 
gebruikt werden voor APLT. Het bleek dat humane hepatocyten in primaire 
kweek in staat zijn om hemostase-eiwitten (t.w. protein C en plasminogeen) 
uit te scheiden in hun kweekmedium. Het gebruik van het verwijderde stuk 
van een donorlever voor m vitro onderzoek Ievert een unieke situatie op, 
waarbij een lever zowel gebruikt wordt voor transplantatie als voor weten-
schappelijk onderzoek. 
Verder klinisch onderzoek, bij zowel orthotope als auxiliaire lever-
transplantaties is noodzakelijk om de klinische relevantie van de beschreven 
verstoringen in de hemostase ten aanzien van het intraoperatieve bloedverlies 
vast te stellen. 
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